UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 __________________________________________________________________________________________

FORM 10-Q

 __________________________________________________________________________________________

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from          to         

Commission File Number 001-36092

 __________________________________________________________________________________________

Premier, Inc.

(Exact name of registrant as specified in its charter)

 ___________________________________________________________________________________________

Delaware		35-2477140
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
13034 Ballantyne Corporate Place
Charlotte,	North Carolina	28277
(Address of principal executive offices)		(Zip Code)

(704) 357-0022

(Registrant’s telephone number, including area code)

 __________________________________________________________________________________________

Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, $0.01 Par Value	PINC	NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒     No   ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  ☒ No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐	Non-accelerated filer	☐
Smaller reporting company	☐	Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   ☐ No   ☒

As of April 29, 2021, there were 122,269,491 shares of the registrant’s Class A common stock, par value $0.01 per share outstanding.

TABLE OF CONTENTS

		Page
PART I. FINANCIAL INFORMATION		6
Item 1.	Financial Statements	6
	Condensed Consolidated Balance Sheets as of March 31, 2021 and June 30, 2020 (Unaudited)	6
	Condensed Consolidated Statements of Income and Comprehensive Income for the three and nine months ended March 31, 2021 and 2020 (Unaudited)	8
	Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the nine months ended March 31, 2021 and 2020 (Unaudited)	10
	Condensed Consolidated Statements of Cash Flows for the nine months ended March 31, 2021 and 2020 (Unaudited)	12
	Notes to Condensed Consolidated Financial Statements (Unaudited)	13
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	35
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	58
Item 4.	Controls and Procedures	58
PART II. OTHER INFORMATION		59
Item 1.	Legal Proceedings	59
Item 1A.	Risk Factors	59
Item 5.	Other Information	59
Item 6.	Exhibits	60
	Signatures	61

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Statements made in this Quarterly Report that are not statements of historical or current facts, such as those under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in conditional or future tenses or that include terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to our beliefs and expectations regarding future events and trends affecting our business and are necessarily subject to uncertainties, many of which are outside our control. Factors that could cause actual results to differ materially from those indicated in any forward-looking statement include, but are not limited to:

•the impact of the continuing financial and operational uncertainty due to the coronavirus pandemic or other pandemics;

•competition which could limit our ability to maintain or expand market share within our industry;

•consolidation in the healthcare industry;

•potential delays recognizing or increasing revenue if the sales cycle or implementation period takes longer than expected;

•the impact on us if members of our group purchasing organization (“GPO”) programs reduce activity levels or terminate or elect not to renew their contracts on substantially similar terms or at all;

•the rate at which the markets for our software as a service (“SaaS”) or licensed-based clinical analytics products and services develop;

•the dependency of our members on payments from third-party payers;

•our reliance on administrative fees that we receive from GPO suppliers;

•our ability to maintain third-party provider and strategic alliances or enter into new alliances;

•our ability to timely offer new and innovative products and services;

•the portion of revenues we receive from our largest members;

•risks and expenses related to future acquisition opportunities and integration of acquisitions;

•financial and operational risks associated with non-controlling investments in other businesses or other joint ventures that we do not control, particularly early-stage companies;

•potential litigation;

•our reliance on Internet infrastructure, bandwidth providers, data center providers and other third parties and our own systems for providing services to our users;

•data loss or corruption due to failures or errors in our systems and service disruptions at our data centers, or breaches or failures of our security measures;

•the financial, operational and reputational consequences of cyber-attacks or other data security breaches that disrupt our operations or result in the dissemination of proprietary or confidential information about us or our members or other third parties;

•our ability to use, disclose, de-identify or license data and to integrate third-party technologies;

•our use of “open source” software;

•our dependency on contract manufacturing facilities located in various parts of the world;

•inventory risk we face in the event of a potential material price decline for the personal protective equipment products we may have purchased at elevated market prices;

•our ability to attract, hire, integrate and retain key personnel;

3

•adequate protection of our intellectual property and potential claims against our use of the intellectual property of third parties;

•potential sales and use tax liability in certain jurisdictions;

•changes in tax laws that materially impact our tax rate, income tax expense, anticipated tax benefits, deferred tax assets, cash flows and profitability;

•our indebtedness and our ability to obtain additional financing on favorable terms, including our ability to renew or replace our existing long-term credit facility at maturity;

•fluctuation of our quarterly cash flows, revenues and results of operations;

•changes and uncertainty in the political, economic or regulatory environment affecting healthcare organizations, including with respect to the status of the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act of 2010;

•our compliance with complex international, federal and state laws governing financial relationships among healthcare providers and the submission of false or fraudulent healthcare claims;

•interpretation and enforcement of current or future antitrust laws and regulations;

•compliance with complex federal and state privacy, security and breach notification laws;

•compliance with current or future laws, rules or regulations adopted by the Food & Drug Administration applicable to our software applications that may be considered medical devices;

•our holding company structure and dependence on distributions from Premier Healthcare Alliance, L.P. (“Premier LP”);

•different interests among our members or between us and our members;

•the ability of our members to exercise significant influence over us;

•the terms of agreements between us and our members;

•the impact of payments required under the Unit Exchange and Tax Receivable Acceleration Agreements (the “Unit Exchange Agreements”) on our overall cash flow and our ability to fully realize the expected tax benefits to match such fixed payment obligations under the Unit Exchange Agreements;

•provisions in our certificate of incorporation and bylaws and provisions of Delaware law that discourage or prevent strategic transactions, including a takeover of us;

•failure to maintain an effective system of internal controls over financial reporting or an inability to remediate any weaknesses identified and the related costs of remediation;

•the impact to us or the price of our Class A common stock if we cease paying dividends or reduce dividend payments from current levels;

•the number of shares of Class A common stock repurchased by us pursuant to any Class A common stock repurchase program and the timing of any such repurchases;

•the number of shares of Class A common stock eligible for sale after the issuance of Class A common stock in our August 2020 restructuring and the potential impact of such sales; and

•the risk factors discussed under the heading “Risk Factors” under Item 1A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2020 (the “2020 Annual Report”), filed with the Securities and Exchange Commission (“SEC”).

More information on potential factors that could affect our financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” or similarly captioned sections of this Quarterly Report and our other periodic and current filings made from time to time with the SEC, which are available on our website at http://investors.premierinc.com/ (the contents of which are not part of this Quarterly Report). You should not place undue reliance on any of our forward-looking statements which speak only as of the date they are made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events or otherwise. Furthermore, we cannot guarantee future results, events, levels of activity, performance or achievements.

4

Certain Definitions

For periods prior to August 11, 2020, references in this Quarterly Report to “member owners” are to the participants in our GPO program that were also limited partners of Premier LP that held Class B common units of Premier LP and shares of our Class B common stock. For periods on or after August 11, 2020, references in this Quarterly Report to “members” are to healthcare provider participants that participate in our GPO program or utilize any of our programs or services, some of which were formerly referred to as member owners.

5

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

PREMIER, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except share data)

	March 31, 2021		June 30, 2020
Assets
Cash and cash equivalents	$	132,584	$	99,304
Accounts receivable (net of $2,137 and $731 allowance for doubtful accounts, respectively)	188,519		135,063
Contract assets	259,331		215,660
Inventory	225,231		70,997
Prepaid expenses and other current assets	83,527		97,338
Total current assets	889,192		618,362
Property and equipment (net of $503,189 and $452,609 accumulated depreciation, respectively)	223,689		206,728
Intangible assets (net of $279,023 and $245,160 accumulated amortization, respectively)	407,531		417,422
Goodwill	999,777		941,965
Deferred income tax assets	821,439		430,025
Deferred compensation plan assets	55,952		49,175
Investments in unconsolidated affiliates	153,747		133,335
Operating lease right-of-use assets	50,556		57,823
Other assets	80,082		93,680
Total assets	$	3,681,965	$	2,948,515
Liabilities, redeemable limited partners' capital and stockholders' equity
Accounts payable	$	100,348	$	54,841
Accrued expenses	64,255		53,500
Revenue share obligations	216,054		145,777
Limited partners' distribution payable	—		8,012
Accrued compensation and benefits	80,234		73,262
Deferred revenue	35,933		35,446
Current portion of tax receivable agreements	—		13,689
Current portion of notes payable to members	95,483		—
Line of credit and current portion of long-term debt	203,964		79,560
Other liabilities	56,574		31,987
Total current liabilities	852,845		496,074
Long-term debt, less current portion	5,333		4,640
Tax receivable agreements, less current portion	—		279,981
Notes payable to members, less current portion	323,156		—
Deferred compensation plan obligations	55,952		49,175
Deferred tax liabilities	—		17,508
Deferred consideration, less current portion	83,700		112,917
Operating lease liabilities, less current portion	45,654		52,990
Other liabilities	100,758		75,658
Total liabilities	1,467,398		1,088,943
Commitments and contingencies (Note 16)
Redeemable limited partners' capital	—		1,720,309

6

	March 31, 2021		June 30, 2020
Stockholders' equity:
Class A common stock, $0.01 par value, 500,000,000 shares authorized; 122,268,758 shares issued and outstanding at March 31, 2021 and 71,627,462 shares issued and outstanding at June 30, 2020	1,223		716
Class B common stock, $0.000001 par value, 600,000,000 shares authorized; 0 and 50,213,098 shares issued and outstanding at March 31, 2021 and June 30, 2020, respectively	—		—
Additional paid-in-capital	2,046,836		138,547
Retained earnings	166,508		—
Total stockholders' equity	2,214,567		139,263
Total liabilities, redeemable limited partners' capital and stockholders' equity	$	3,681,965	$	2,948,515

See accompanying notes to the unaudited condensed consolidated financial statements.

7

PREMIER, INC.

Condensed Consolidated Statements of Income and Comprehensive Income

(Unaudited)

(In thousands, except per share data)

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2021		2020		2021		2020
Net revenue:
Net administrative fees	$	146,553	$	174,049	$	424,537	$	518,566
Other services and support	107,375		99,591		304,020		270,929
Services	253,928		273,640		728,557		789,495
Products	215,995		61,183		511,080		167,344
Net revenue	469,923		334,823		1,239,637		956,839
Cost of revenue:
Services	46,980		49,007		125,852		143,965
Products	211,136		54,121		496,286		150,415
Cost of revenue	258,116		103,128		622,138		294,380
Gross profit	211,807		231,695		617,499		662,459
Operating expenses:
Selling, general and administrative	134,502		115,289		388,453		315,311
Research and development	715		628		2,013		1,808
Amortization of purchased intangible assets	10,400		13,966		33,864		38,948
Operating expenses	145,617		129,883		424,330		356,067
Operating income	66,190		101,812		193,169		306,392
Equity in net income of unconsolidated affiliates	5,524		4,442		16,023		11,038
Interest and investment loss, net	(3,225)		(9,966)		(8,742)		(9,849)
(Loss) gain on FFF put and call rights	(5,195)		(13,906)		(21,621)		8,477
Other income (expense), net	1,594		(5,005)		10,167		(1,996)
Other (expense) income, net	(1,302)		(24,435)		(4,173)		7,670
Income before income taxes	64,888		77,377		188,996		314,062
Income tax expense (benefit)	13,444		4,165		(88,037)		78,336
Net income from continuing operations	51,444		73,212		277,033		235,726
Income from discontinued operations, net of tax	—		5		—		1,009
Net income	51,444		73,217		277,033		236,735
Net income from continuing operations attributable to non-controlling interest	(3,123)		(35,055)		(15,903)		(132,189)
Net income from discontinued operations attributable to non-controlling interest	—		(3)		—		(480)
Net income attributable to non-controlling interest	(3,123)		(35,058)		(15,903)		(132,669)
Adjustment of redeemable limited partners' capital to redemption amount	—		302,569		(26,685)		516,725
Net income attributable to stockholders	$	48,321	$	340,728	$	234,445	$	620,791
Comprehensive income:
Net income	51,444		73,217		277,033		236,735
Less: comprehensive income attributable to non-controlling interest	(3,123)		(35,058)		(15,903)		(132,669)
Comprehensive income attributable to stockholders	$	48,321	$	38,159	$	261,130	$	104,066
Weighted average shares outstanding:
Basic	122,254		69,451		114,596		65,582
Diluted	123,116		122,470		115,365		124,030

8

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2021		2020		2021		2020
Earnings per share attributable to stockholders:
Basic earnings per share attributable to stockholders	$	0.40	$	4.91	$	2.05	$	9.47
Diluted earnings per share attributable to stockholders	$	0.39	$	0.54	$	2.03	$	1.66

See accompanying notes to the unaudited condensed consolidated financial statements.

9

PREMIER, INC.

Condensed Consolidated Statements of Stockholders' Equity (Deficit)

Nine Months Ended March 31, 2021 and 2020

(Unaudited)

(In thousands)

	Class A Common Stock			Class B Common Stock			Treasury Stock			Additional Paid-In Capital		Retained Earnings / (Accumulated Deficit)		Total Stockholders' Equity
	Shares	Amount		Shares	Amount		Shares	Amount
Balance at June 30, 2020	71,627	$	716	50,213	$	—	—	$	—	$	138,547	$	—	$	139,263
Balance at July 1, 2020	71,627	716		50,213	—		—	—		138,547		—		139,263
Impact of change in accounting principle	—	—		—	—		—	—		—		(1,228)		(1,228)
Adjusted balance at July 1, 2020	71,627	716		50,213	—		—	—		138,547		(1,228)		138,035
Exchange of Class B common units for Class A common stock by member owners	70	1		(70)	—		—	—		2,436		—		2,437
Increase in additional paid-in capital related to quarterly exchange by member owners, including associated TRA revaluation	—	—		—	—		—	—		37,319		—		37,319
Increase in additional paid-in capital related to final exchange by member owners, including TRA termination	—	—		—	—		—	—		517,526		—		517,526
Issuance of Class A common stock under equity incentive plan	241	2		—	—		—	—		642		—		644
Stock-based compensation expense	—	—		—	—		—	—		7,229		—		7,229
Repurchase of vested restricted units for employee tax-withholding	—	—		—	—		—	—		(3,023)		—		(3,023)
Net income	—	—		—	—		—	—		—		180,685		180,685
Net income attributable to non-controlling interest	—	—		—	—		—	—		—		(11,845)		(11,845)
Adjustment of redeemable limited partners' capital to redemption amount	—	—		—	—		—	—		—		(26,685)		(26,685)
Reclassification of redeemable limited partners' capital to permanent equity	—	—		—	—		—	—		1,750,840		3,767		1,754,607
Final exchange of Class B common units for Class A common stock by member owners	50,143	502		(50,143)	—		—	—		(502)		—		—
Early Termination Payments to members	—	—		—	—		—	—		(438,967)		—		(438,967)
Dividends ($0.19 per share)	—	—		—	—		—	—		—		(23,381)		(23,381)
Balance at September 30, 2020	122,081	1,221		—	—		—	—		2,012,047		121,313		2,134,581
Issuance of Class A common stock under equity incentive plan	102	1		—	—		—	—		1,770		—		1,771
Issuance of Class A common stock under employee stock purchase plan	45	—		—	—		—	—		1,597		—		1,597
Stock-based compensation expense	—	—		—	—		—	—		7,316		—		7,316
Repurchase of vested restricted units for employee tax-withholding	—	—		—	—		—	—		(28)		—		(28)
Net income	—	—		—	—		—	—		—		44,904		44,904
Net income attributable to non-controlling interest	—	—		—	—		—	—		935		(935)		—
Dividends ($0.19 per share)	—	—		—	—		—	—		—		(23,374)		(23,374)
Adjustment in additional paid-in capital related to consolidated investment	—	—		—	—		—	—		318		(318)		—
Capital Contributions	—	—		—	—		—	—		1,959		—		1,959
Non-controlling interest in consolidated investments	—	—		—	—		—	—		3,690		—		3,690
Balance at December 31, 2020	122,228	1,222		—	—		—	—		2,029,604		141,590		2,172,416
Issuance of Class A common stock under equity incentive plan	40	1		—	—		—	—		1,101		—		1,102
Stock-based compensation expense	—	—		—	—		—	—		13,056		—		13,056
Repurchase of vested restricted units for employee tax-withholding	—	—		—	—		—	—		(48)		—		(48)
Net income	—	—		—	—		—	—		—		51,444		51,444
Net income attributable to non-controlling interest	—	—		—	—		—	—		3,123		(3,123)		—
Dividends ($0.19 per share)	—	—		—	—		—	—		—		(23,403)		(23,403)
Balance at March 31, 2021	122,268	$	1,223	—	$	—	—	$	—	$	2,046,836	$	166,508	$	2,214,567

10

	Class A Common Stock			Class B Common Stock			Treasury Stock			Additional Paid-In Capital		Accumulated Deficit		Total Stockholders’ Equity (Deficit)
	Shares	Amount		Shares	Amount		Shares	Amount
Balance at June 30, 2019	61,938	$	644	64,548	$	—	2,419	$	(87,220)	$	—	$	(775,674)	$	(862,250)
Balance at July 1, 2019	61,938	644		64,548	—		2,419	(87,220)		—		(775,674)		(862,250)
Impact of change in accounting principle	—	—		—	—		—	—		—		(899)		(899)
Adjusted balance at July 1, 2019	61,938	644		64,548	—		2,419	(87,220)		—		(776,573)		(863,149)
Exchange of Class B common units for Class A common stock by member owners	1,311	—		(1,311)	—		(1,311)	47,258		3,534		—		50,792
Redemption of limited partners	—	—		(782)	—		—	—		—		—		—
Increase in additional paid-in capital related to quarterly exchange by member owners, including associated TRA revaluation	—	—		—	—		—	—		12,272		—		12,272
Issuance of Class A common stock under equity incentive plan	485	5		—	—		—	—		1,749		—		1,754
Treasury stock	(1,055)	—		—	—		1,055	(35,649)		—		—		(35,649)
Stock-based compensation expense	—	—		—	—		—	—		3,704		—		3,704
Repurchase of vested restricted units for employee tax-withholding	—	—		—	—		—	—		(8,311)		—		(8,311)
Net income	—	—		—	—		—	—		—		71,329		71,329
Net income attributable to non-controlling interest in Premier LP	—	—		—	—		—	—		—		(41,907)		(41,907)
Adjustment of redeemable limited partners' capital to redemption amount	—	—		—	—		—	—		(12,948)		707,257		694,309
Balance at September 30, 2019	62,679	649		62,455	—		2,163	(75,611)		—		(39,894)		(114,856)
Exchange of Class B units for Class A common stock by member owners	6,873	19		(6,873)	—		(5,031)	164,810		59,117		—		223,946
Increase in additional paid-in capital related to departure and quarterly exchange by member owners, including associated TRA revaluation	—	—		—	—		—	—		1,103		—		1,103
Issuance of Class A common stock under equity incentive plan	146	1		—	—		—	—		4,243		—		4,244
Issuance of Class A common stock under employee stock purchase plan	40	—		—	—		—	—		1,540		—		1,540
Treasury stock	(3,549)	—		—	—		3,549	(112,917)		—		—		(112,917)
Stock-based compensation expense	—	—		—	—		—	—		7,775		—		7,775
Repurchase of vested restricted units for employee tax-withholding	—	—		—	—		—	—		(47)		—		(47)
Net income	—	—		—	—		—	—		—		92,189		92,189
Net income attributable to non-controlling interest in Premier LP	—	—		—	—		—	—		—		(55,704)		(55,704)
Adjustment of redeemable limited partner's capital to redemption amount	—	—		—	—		—	—		(73,731)		(406,422)		(480,153)
Balance at December 31, 2019	66,189	669		55,582	—		681	(23,718)		—		(409,831)		(432,880)
Exchange of Class B units for Class A common stock by member owners	4,866	41		(4,866)	—		(723)	25,245		143,908		—		169,194
Increase in additional paid-in capital related to departure and quarterly exchange by member owners, including associated TRA revaluation	—	—		—	—		—	—		58,193		—		58,193
Issuance of Class A common stock under equity incentive plan	58	1		—	—		—	—		308		—		309
Treasury stock	(42)	—		—	—		42	(1,527)		—		—		(1,527)
Stock-based compensation expense	—	—		—	—		—	—		7,568		—		7,568
Repurchase of vested restricted units for employee tax-withholding	—	—		—	—		—	—		(123)		—		(123)
Net income	—	—		—	—		—	—		—		73,217		73,217
Net income attributable to non-controlling interest in Premier LP	—	—		—	—		—	—		—		(35,058)		(35,058)
Adjustment of redeemable limited partner's capital to redemption amount	—	—		—	—		—	—		(69,103)		371,672		302,569
Balance at March 31, 2020	71,071	$	711	50,716	$	—	—	$	—	$	140,751	$	—	$	141,462

See accompanying notes to the unaudited condensed consolidated financial statements.

11

PREMIER, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

	Nine Months Ended March 31,
	2021		2020
Operating activities
Net income	$	277,033	$	236,735
Adjustments to reconcile net income to net cash provided by operating activities:
Income from discontinued operations, net of tax	—		(1,009)
Depreciation and amortization	89,768		114,638
Equity in net income of unconsolidated affiliates	(16,023)		(11,038)
Deferred income taxes	(123,307)		60,394
Stock-based compensation	27,601		19,048
Remeasurement of tax receivable agreement liabilities	—		(24,584)
Impairment of held to maturity investments	—		8,500
Loss (gain) on FFF put and call rights	21,621		(8,477)
Other	537		2,078
Changes in operating assets and liabilities, net of the effects of acquisitions:
Accounts receivable, inventories, prepaid expenses and other assets	(181,263)		(95,953)
Contract assets	(43,733)		(28,909)
Accounts payable, accrued expenses, deferred revenue, revenue share obligations and other liabilities	140,131		(23,341)
Net cash provided by operating activities from continuing operations	192,365		248,082
Net cash provided by operating activities from discontinued operations	—		9,338
Net cash provided by operating activities	192,365		257,420
Investing activities
Purchases of property and equipment	(66,911)		(69,326)
Acquisition of businesses, net of cash acquired	(81,152)		(96,346)
Investments in unconsolidated affiliates	—		(10,165)
Other	(1,228)		3,883
Net cash used in investing activities	(149,291)		(171,954)
Financing activities
Payments made on notes payable	(31,692)		(2,046)
Proceeds from credit facility	225,000		375,000
Payments on credit facility	(100,000)		(150,000)
Distributions to limited partners of Premier LP	(9,949)		(39,590)
Payments to limited partners of Premier LP related to tax receivable agreements	(24,218)		(17,425)
Cash dividends paid	(69,647)		—
Repurchase of Class A common stock (held as treasury stock)	—		(150,093)
Other	712		(633)
Net cash (used in) provided by financing activities	(9,794)		15,213
Net increase in cash and cash equivalents	33,280		100,679
Cash and cash equivalents at beginning of year	99,304		141,055
Cash and cash equivalents at end of period	$	132,584	$	241,734

See accompanying notes to the unaudited condensed consolidated financial statements.

12

PREMIER, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(1) ORGANIZATION AND BASIS OF PRESENTATION

Organization

Premier, Inc. (“Premier” or the “Company”) is a publicly held, for-profit Delaware corporation located in the United States. The Company is a holding company with no material business operations of its own. The Company’s primary asset is its equity interest in its wholly owned subsidiary Premier Services, LLC, a Delaware limited liability company (“Premier GP”). Premier GP is the sole general partner of Premier Healthcare Alliance, L.P. (“Premier LP”), a California limited partnership. The Company conducts substantially all of its business operations through Premier LP and its other consolidated subsidiaries. The Company, together with its subsidiaries and affiliates, is a leading healthcare performance improvement company that unites hospitals, health systems, physicians and other healthcare providers to improve and innovate in the clinical, financial and operational areas of their businesses to meet the demands of a rapidly evolving healthcare industry. The Company also provides services to non-healthcare businesses.

The Company’s business model and solutions are designed to provide its members and other customers access to scale efficiencies, spread the cost of their development, provide actionable intelligence derived from anonymized data in the Company’s enterprise data warehouse, mitigate the risk of innovation and disseminate best practices to help the Company’s member organizations and other customers succeed in their transformation to higher quality and more cost-effective healthcare.

The Company, together with its subsidiaries and affiliates, delivers its integrated platform of solutions through two business segments: Supply Chain Services and Performance Services. See Note 17 - Segments for further information related to the Company’s reportable business segments. The Supply Chain Services segment includes one of the largest healthcare group purchasing organization (“GPO”) programs in the United States, supply chain co-management and direct sourcing activities. The Performance Services segment, through its development, integration and delivery of technology with wrap-around service offerings, includes one of the largest clinical and cost analytics and consulting services businesses in the United States focused on healthcare providers. The Company is also expanding its capabilities to more fully address and coordinate care improvement and standardization in the employer, payor and life sciences markets. The Company’s software as a service (“SaaS”) and licensed-based clinical analytics products utilize the Company’s comprehensive data set to provide actionable intelligence to its members and other customers, enabling them to benchmark, analyze and identify areas of improvement across the three main categories of cost management, quality and safety, and value-based care. While leveraging these tools, the Company also combines its consulting services and technology-enabled performance improvement collaboratives to provide a more comprehensive and holistic customer value proposition and overall experience. The Performance Services segment also includes the Company’s direct-to-employer initiative and insurance management services.

Acquisitions and Divestitures

Acquisition of Invoice Delivery Services, LP Assets

On March 1, 2021, the Company, through a newly formed consolidated subsidiary, Premier IDS, LLC (“Premier IDS”), acquired substantially all the assets and assumed certain liabilities of Invoice Delivery Services, LP (“IDS”) for an adjusted purchase price of $80.4 million, subject to certain adjustments, of which $80.0 million was paid at closing with borrowings under the Company’s Credit Facility (as defined below).

IDS offers digitization technologies that convert paper and portable document format (“PDF”) invoices to an electronic format to automate, streamline and simplify accounts payable processes in healthcare. IDS’ solutions include those for electronic invoicing and tracking, as well as digital payments. IDS will be integrated within Premier under the brand name RemitraTM and reported as part of the Performance Services segment. See Note 3 - Business Acquisitions for further information.

Company Structure and Restructuring

The Company, through Premier GP and Premier Services II, LLC, a Delaware limited liability company that is a wholly owned subsidiary of the Company and the sole limited partner of Premier LP, held a 100% interest in Premier LP at March 31, 2021. At June 30, 2020, the Company held a 59% sole general partner interest in Premier LP. At March 31, 2021 and June 30, 2020, members held a 0% and 41% limited partner interest in Premier LP, respectively. On July 31, 2020, after the resignation of three directors affiliated with the Company’s members, the Board of Directors consisted of fifteen (15) directors, comprised of eight (8) independent directors, six (6) member-directors and the Company’s Chief Executive Officer, thus having a majority of independent directors on the Board of Directors. Since the member-directors no longer comprised a majority of the Board of Directors as of July 31, 2020, the limited partner’s redemption feature was under the control of the Company (not the holders of

13

Class B common units). As a result, $1.8 billion representing the fair value of redeemable limited partners’ capital at July 31, 2020 was reclassified from temporary equity in the mezzanine section of the Condensed Consolidated Balance Sheets to additional paid in capital as a component of permanent equity.

On August 11, 2020, the Company entered into an Agreement and Plan of Merger dated as of August 11, 2020 (the “Merger Agreement”), by and among the Company, Premier LP and BridgeCo, LLC (“BridgeCo”), a wholly owned subsidiary of Premier Services, LLC formed for the sole purpose of merging with and into Premier LP. Pursuant to the Merger Agreement, effective August 11, 2020, (i) BridgeCo merged with and into Premier LP, with Premier LP being the surviving entity (the “Merger”), and (ii) each of the issued and outstanding Class B common units of Premier LP was canceled and converted automatically into a right to receive one share of the Company’s Class A common stock. In conjunction with the Merger, all of the issued and outstanding shares of Class B common stock of the Company beneficially held by the former limited partners of Premier LP (individually a “LP” and collectively, the “LPs”) were canceled in accordance with the Company’s Certificate of Incorporation. The exchange agreement (“Exchange Agreement”), which allowed the Company to settle Class B common units submitted for exchange by LPs for cash, Class A common stock or a combination thereof at its discretion, was terminated in connection with the restructuring activity discussed above.

Furthermore, on August 10, 2020, the Company exercised its right to terminate the Tax Receivable Agreement (“TRA”). See Note 9 - Debt and Notes Payable and Note 14 - Income Taxes for further information.

Basis of Presentation and Consolidation

Basis of Presentation

At March 31, 2021, the Company was wholly owned by public investors, which included member owners that received shares of Class A common stock in connection with the aforementioned restructuring as well as previous exchanges of Class B common units and associated Class B common stock.

At June 30, 2020, the member owners’ interest in Premier LP was reflected as redeemable limited partners’ capital in the Company’s accompanying Condensed Consolidated Balance Sheets, and the limited partners’ proportionate share of income in Premier LP was reflected within net income attributable to non-controlling interest and within comprehensive income attributable to non-controlling interest in the Company’s accompanying Condensed Consolidated Statements of Income and Comprehensive Income.

At June 30, 2020, public investors, which included member owners that received shares of Class A common stock in connection with previous exchanges of their Class B common units and associated Class B common shares, owned 59% of the Company’s outstanding common stock through their ownership of Class A common stock. The member owners owned 41% of the Company’s combined Class A and Class B common stock through their ownership of Class B common stock.

Principles of Consolidation

The accompanying condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC and in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and include the assets, liabilities, revenues and expenses of all majority-owned subsidiaries over which the Company exercised control and when applicable, entities for which the Company had a controlling financial interest or was the primary beneficiary. All intercompany transactions have been eliminated upon consolidation. Accordingly, certain information and disclosures normally included in annual financial statements have been condensed or omitted. The accompanying condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair presentation of results of operations and financial condition for the interim periods shown, including normal recurring adjustments. The Company believes that the disclosures are adequate to make the information presented not misleading and should be read in conjunction with the audited consolidated financial statements and related footnotes contained in the 2020 Annual Report.

14

Supplementary Cash Flows Information

The following table presents supplementary cash flows information for the nine months ended March 31, 2021 and 2020 (in thousands):

	Nine Months Ended March 31,
	2021		2020
Supplemental schedule of non-cash investing and financing activities:
Increase (decrease) in redeemable limited partners' capital for adjustment to fair value, with offsetting decrease (increase) in stockholders' equity	$	26,685	$	(516,725)
Decrease in redeemable limited partners' capital, with offsetting increase in stockholders' equity related to quarterly exchanges by member owners	(2,437)		(443,931)
Net increase in deferred tax assets related to departures and quarterly exchanges by member owners and other adjustments	331		63,958
Net increase in deferred tax assets related to final exchange by member owners	284,852		—
Reclassification of redeemable limited partners' capital to additional paid in capital	1,754,607		—
Decrease in additional paid-in capital related to notes payable to members, net of discounts	438,967		—
Net increase in additional paid-in capital related to departures and quarterly exchanges by member owners and other adjustments	37,319		71,568
Increase in additional paid-in capital related to final exchange by member owners	517,526		—
Accrued dividend equivalents	513		—

Variable Interest Entities

At March 31, 2021, as a result of the aforementioned restructuring, Premier LP no longer meets the definition of a variable interest entity (“VIE”), as defined in Accounting Standards Codification (“ASC”) Topic 810. The results of operations of Premier LP are included in the condensed consolidated financial statements.

At June 30, 2020, Premier LP was a VIE as the limited partners did not have the ability to exercise a substantive removal right with respect to the general partner. The Company, through Premier GP, had the exclusive power and authority to manage the business and affairs of Premier LP, to make all decisions with respect to driving the economic performance of Premier LP, and had both an obligation to absorb losses and a right to receive benefits. As such, the Company was the primary beneficiary of the VIE and consolidated the operations of Premier LP under the Variable Interest Model.

The assets and liabilities of Premier LP at June 30, 2020, including assets and liabilities of discontinued operations, consisted of the following (in thousands):

	June 30, 2020
Assets
Current	$	610,990
Noncurrent	1,900,137
Total assets of Premier LP	$	2,511,127
Liabilities
Current	$	580,430
Noncurrent	296,801
Total liabilities of Premier LP	$	877,231

Net income attributable to Premier LP, including income and expense that has been classified as discontinued operations, during the three and nine months ended March 31, 2020 was as follows (in thousands):

	Three Months Ended March 31, 2020		Nine Months Ended March 31, 2020
Premier LP net income	$	84,185	$	290,430

15

Premier LP’s cash flows, including cash flows attributable to discontinued operations, for the nine months ended March 31, 2020 consisted of the following (in thousands):

	Nine Months Ended March 31, 2020
Net cash provided by (used in):
Operating activities	$	252,566
Investing activities	(171,954)
Financing activities	24,790
Net increase in cash and cash equivalents	105,402
Cash and cash equivalents at beginning of year	131,210
Cash and cash equivalents at end of period	$	236,612

Use of Estimates in the Preparation of Financial Statements

The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. Significant estimates are evaluated on an ongoing basis, including estimates for net administrative fees revenue, other services and support revenue, contract assets, deferred revenue, contract costs, allowances for doubtful accounts, useful lives of property and equipment, stock-based compensation, deferred tax balances including valuation allowances on deferred tax assets, uncertain tax positions, values of investments not publicly traded, projected future cash flows used in the evaluation of asset impairments, values of put and call rights, values of earn-out liabilities and the allocation of purchase prices. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

(2) SIGNIFICANT ACCOUNTING POLICIES

There have been no material changes to the Company’s significant accounting policies as described in the 2020 Annual Report, except as described below.

Accounts Receivable

Financial instruments, other than marketable securities, that subject the Company to potential concentrations of credit risk consist primarily of the Company's receivables. Receivables consist primarily of amounts due from hospital and healthcare system members for services and products. The Company maintains an allowance for expected credit losses. This allowance is an estimate and is regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the member and other customer base and age of the receivable balances, both individually and in the aggregate. As receivables are generally due within one year, changes to economic conditions are not expected to have a significant impact on our estimate of expected credit losses. However, we will monitor economic conditions on a quarterly basis to determine if any adjustments are deemed necessary. Provisions for the allowance for expected credit losses attributable to bad debt are recorded in selling, general and administrative expenses in the accompanying Consolidated Statements of Income and Comprehensive Income. Accounts deemed uncollectible are written off, net of actual recoveries. If circumstances related to specific customers change, the Company's estimate of the recoverability of receivables could be further adjusted.

Contract Assets

Supply Chain Services contract assets represents estimated member and other customer purchases on supplier contracts for which administrative fees have been earned, but not collected. Performance Services contract assets represents revenue earned for services provided but which the company is not contractually able to bill as of the end of the respective reporting period. Historically, we have not recognized a provision for contract assets. Under ASC Topic 326, we include Performance Services’ contract assets in our reserving process and assess the risk of loss similar to our methodology of the Company’s receivables, since the contract assets are reclassified to receivables when we become entitled to payment. Accordingly, a reserve is applied upon recognition of the contract asset.

Recently Adopted Accounting Standards

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, (“ASU 2016-13”), which modifies the measurement of expected credit losses on certain financial

16

instruments and the timing of when such losses are recorded. The Company adopted ASU 2016-13 effective July 1, 2020 on a modified retrospective basis which resulted in a reduction to retained earnings of $1.2 million.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, (“ASU 2018-13”), which improves the effectiveness of fair value measurement disclosures by eliminating, adding and modifying certain disclosure requirements for fair value measurements as part of its disclosure framework project. Entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but public companies will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The Company adopted ASU 2018-13 effective July 1, 2020 and has updated the financial statements accordingly to reflect the updates in the disclosure requirements (see Note 6 - Fair Value Measurements). The implementation of ASU 2018-13 did not have a material effect on the Company’s condensed consolidated financial statements.

In August 2018, the FASB issued ASU 2018-15, Intangibles- Goodwill and Other-Internal Use Software (Topic 350): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract, (“ASU 2018-15”), which requires customers in a cloud computing arrangement (i.e., hosting arrangement) that is a service contract to follow the internal use software guidance in ASC 350-40 to determine which implementation costs to capitalize or expense. The Company adopted ASU 2018-15 effective July 1, 2020 on a prospective basis. The implementation of ASU 2018-15 did not have a material effect on the Company’s condensed consolidated financial statements.

(3) BUSINESS ACQUISITIONS

Acquisition of Invoice Delivery Services, LP Assets

On March 1, 2021, the Company, through Premier IDS, acquired substantially all the assets and assumed certain liabilities of IDS for an adjusted purchase price of $80.4 million, subject to certain adjustments, of which $80.0 million was paid at closing with borrowings under the Company’s Credit Facility (the “IDS Acquisition”).

The Company has accounted for the IDS Acquisition as a business combination whereby the purchase price was allocated to tangible and intangible assets acquired and liabilities assumed based on their fair values. The total fair value assigned to intangible assets acquired was $22.4 million, consisting primarily of developed technology.

The IDS Acquisition resulted in the recognition of $57.5 million of goodwill (see Note 8 - Goodwill and Intangible Assets) attributable to the anticipated profitability of IDS. The IDS Acquisition was considered an asset acquisition for income tax purposes. Accordingly, the Company expects tax goodwill to be deductible for tax purposes. The initial purchase price allocation for the IDS Acquisition is preliminary and subject to changes in fair value of working capital and valuation of the assets acquired. IDS will be integrated within Premier under the brand name RemitraTM and reported as part of the Performance Services segment.

Acquisition of Health Design Plus, LLC

On May 4, 2020, the Company, through its consolidated subsidiary Premier Healthcare Solutions, Inc. (“PHSI”), acquired 97% of the equity of Health Design Plus, LLC (“HDP”) for an adjusted purchase price of $23.8 million, giving effect to certain purchase price adjustments provided for in the purchase agreement. The transaction was funded with borrowings under the Company’s Credit Facility.

The purchase price allocation was finalized during the three months ended December 31, 2020.

Acquisition of Acurity and Nexera Assets

On February 28, 2020, the Company acquired substantially all of the assets and certain liabilities of Acurity, Inc. and Nexera, Inc. (the “Acurity and Nexera asset acquisition”). The Company agreed to pay an aggregate amount of $291.5 million, of which $166.1 million was paid at closing with borrowings under the Credit Facility. An additional $120.0 million will be paid in four equal annual installments of $30.0 million on or about June 30, 2021, 2022, 2023 and 2024. An additional $4.7 million was paid to GNYHA during the three months ended September 30, 2020.

In addition, the asset purchase agreement provides an earn-out opportunity for Acurity, Inc. of up to $30.0 million based upon the Company’s achievement of a range of member renewals on terms to be agreed to by the Company and GNYHA based on prevailing market conditions in December 2023. As of March 31, 2021, the fair value of the earn-out liability was $24.0 million (see Note 6 - Fair Value Measurements).

17

Prior to entering into the purchase agreement, Acurity, Inc. agreed to provide one-time rebates of $93.8 million to certain of its then members based on their pre-closing purchasing volume. The Company concluded that these one-time rebates should be excluded from the purchase price and capitalized as prepaid contract administrative fee share at closing. As a result, the total fair value of consideration paid as part of the acquisition totaled $202.6 million.

The purchase price allocation was finalized during the three months ended September 30, 2020.

Acquisition of Medpricer

On October 28, 2019, the Company, through its consolidated subsidiary Premier Supply Chain Improvement, Inc. (“PSCI”), acquired all of the outstanding capital stock in Medpricer.com, Inc. (“Medpricer”) for an adjusted purchase price of $38.5 million. The transaction was funded with borrowings under the Credit Facility.

The acquisition provides the sellers an earn-out opportunity of up to $5.0 million based on Medpricer’s achievement of a revenue target for the calendar year ended December 31, 2020. As of March 31, 2021, the value of the earn-out liability was $4.8 million.

The purchase price allocation was finalized during the three months ended September 30, 2020.

(4) DISCONTINUED OPERATIONS AND EXIT ACTIVITIES

In connection with the sale of certain assets and wind down and exit from the specialty pharmacy business, the Company met the criteria for classifying certain assets and liabilities of its specialty pharmacy business as a discontinued operation as of June 30, 2019. Prior to its classification as a discontinued operation, the specialty pharmacy business was included as part of the Supply Chain Services segment.

As of June 30, 2020, the Company had completed the wind down and exit from the specialty pharmacy business and had no net income or loss from discontinued operations for the three and nine months ended March 31, 2021.

The following table summarizes the major components of net income from discontinued operations (in thousands):

	Three Months Ended March 31, 2020		Nine Months Ended March 31, 2020
Operating gain from discontinued operations	$	—	$	—
Net gain on disposal of assets	24		1,399
Income from discontinued operations before income taxes	24		1,399
Income tax expense	19		390
Income from discontinued operations, net of tax	5		1,009
Net income from discontinued operations attributable to non-controlling interest in Premier LP	(3)		(480)
Net income from discontinued operations attributable to stockholders	$	2	$	529

(5) INVESTMENTS

Investments in Unconsolidated Affiliates

The Company’s investments in unconsolidated affiliates consisted of the following (in thousands):

	Carrying Value				Equity in Net Income
					Three Months Ended				Nine Months Ended
					March 31,				March 31,
	March 31, 2021		June 30, 2020		2021		2020		2021		2020
FFF	$	117,591	$	109,204	$	806	$	4,340	$	8,387	$	10,830
Prestige	18,276		11,194		4,436		—		7,082		—
Other investments	17,880		12,937		282		102		554		208
Total investments	$	153,747	$	133,335	$	5,524	$	4,442	$	16,023	$	11,038

18

The Company, through PSCI, held a 49% interest in FFF Enterprises, Inc. (“FFF”) through its ownership of stock of FFF at March 31, 2021 and June 30, 2020. The Company records the fair value of the FFF put and call rights in the accompanying Condensed Consolidated Balance Sheets (see Note 6 - Fair Value Measurements for additional information). The Company accounts for its investment in FFF using the equity method of accounting and includes the investment as part of the Supply Chain Services segment.

The Company, through its consolidated subsidiary, PRAM Holdings, LLC (“PRAM”), held an approximate 20% interest in Prestige Ameritech Ltd. (“Prestige”) through its ownership of Prestige limited partnership units at March 31, 2021. The Company owns approximately 26% of the membership interest of PRAM, with the remainder of the membership interests held by 16 member health systems. The Company accounts for its investment in Prestige using the equity method of accounting and includes the investment as part of the Supply Chain Services segment.

(6) FAIR VALUE MEASUREMENTS

Recurring Fair Value Measurements

The following tables provide for the periods presented a summary of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):

March 31, 2021	Fair Value of Financial Assets and Liabilities		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	75	$	75	$	—	$	—
Deferred compensation plan assets	61,107		61,107		—		—
Total assets	61,182		61,182		—		—
Earn-out liabilities	23,954		—		—		23,954
FFF put right	58,379		—		—		58,379
Total liabilities	$	82,333	$	—	$	—	$	82,333

June 30, 2020	Fair Value of Financial Assets and Liabilities		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	13,272	$	13,272	$	—	$	—
Deferred compensation plan assets	52,538		52,538		—		—
Total assets	65,810		65,810		—		—
Earn-out liability	33,151		—		—		33,151
FFF put right	36,758		—		—		36,758
Total liabilities	$	69,909	$	—	$	—	$	69,909

Deferred compensation plan assets consisted of highly liquid mutual fund investments, which were classified as Level 1. The current portion of deferred compensation plan assets ($5.2 million and $3.4 million at March 31, 2021 and June 30, 2020, respectively) was included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets.

Financial Instruments Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3)

FFF put and call rights

In connection with the Company’s equity investment in FFF, the Company entered into a shareholders’ agreement that provides, among other things, that the majority shareholder of FFF holds a put right that requires the Company to purchase the majority shareholder’s interest in FFF, on an all or nothing basis, on or after April 15, 2023. Any required purchase by the Company upon exercise of the put right by FFF’s majority shareholder must be made at a per share price equal to FFF’s earnings before interest, taxes, depreciation and amortization (“EBITDA”) over the twelve calendar months prior to the purchase date multiplied by a market adjusted multiple, adjusted for any outstanding debt and cash and cash equivalents (“Equity Value per Share”). In addition, in the event of a Key Man Event (generally defined in the shareholders’ agreement as the resignation, termination for cause, death or disability of the majority shareholder), the Company has a call right that requires the majority shareholder to sell its remaining interest in FFF to the Company, and is exercisable at any time within the later of

19

180 calendar days after (i) the date of a Key Man Event or (ii) January 30, 2021. As of March 31, 2021 and June 30, 2020, the call right had zero value. In the event that either of these rights are exercised, the purchase price for the additional interest in FFF will be at a per share price equal to the Equity Value per Share.

The fair values of the FFF put and call rights were determined using a Monte Carlo simulation in a risk-neutral framework based on the Equity Value per Share calculation using unobservable inputs, which included the estimated FFF put and call rights’ expiration dates, the forecast of FFF’s EBITDA and enterprise value over the option period, forecasted movements in the overall market and the likelihood of a Key Man Event. FFF’s enterprise value over the option period was valued utilizing expected annual EBITDA and Revenue growth rates, among other assumptions. The resulting FFF enterprise value was an assumption utilized in the valuation of the put and call rights. Significant increases to weighted average cost of capital, business enterprise value, correlation and credit spread could significantly decrease the liability while a significant increase to asset volatility, EBITDA growth rate and revenue growth rate could significantly increase the liability.

The Company utilized the following assumptions to estimate the fair value of FFF Put and Call Rights:

	March 31, 2021		June 30, 2020
Annual EBITDA growth rate	2.5-10.8%		2.5-26.5%
Annual revenue growth rate	2.5-6.3%		1.4-14.4%
Correlation	80.0	%	80.0	%
Weighted average cost of capital	14.0	%	14.5	%
Asset volatility	30.0	%	28.0	%
Credit spread	0.9	%	1.7	%

The significant assumptions using the Monte Carlo simulation approach for valuation of the Put and Call Rights are:

(i)Annual EBITDA Growth Rate: The forecasted EBITDA growth range over six years;

(ii)Annual Revenue Growth Rate: The forecasted Revenue growth range over six years;

(iii)Correlation: The estimated correlation between future Business Enterprise Value and EBITDA of FFF;

(iv)Weighted Average Cost of Capital: The expected rate paid to security holders to finance debt and equity;

(v)Asset volatility: Based on the asset volatility of guideline public companies in the healthcare industry; and

(vi)Credit Spread: Based on term-matched BBB yield curve.

The Company recorded the FFF put and call rights within long-term other liabilities and long-term other assets, respectively, within the accompanying Condensed Consolidated Balance Sheets. Net changes in the fair values of the FFF put and call rights were recorded within other (expense) income, net in the accompanying Condensed Consolidated Statements of Income and Comprehensive Income.

Earn-out liabilities

Earn-out liabilities were established in connection with the Acurity and Nexera asset acquisition and the Stanson Health, Inc. (“Stanson”) and Medpricer acquisitions. The earn-out liability associated with the Acurity and Nexera asset acquisition was classified as Level 3 of the fair value hierarchy. The earn-out liability associated with the Medpricer acquisition is no longer measured at fair value as of March 31, 2021, given Medpricer’s achievement of a portion of the earn-out. The full earn-out associated with the Stanson acquisition was paid to former employees and shareholders as of December 31, 2020.

The earn-out liability arising from expected earn-out payments related to the Acurity and Nexera asset acquisition were measured on the acquisition date using a probability-weighted expected payment model and are remeasured periodically due to changes in management’s estimates of the number of member renewals and market conditions. In determining the fair value of the contingent liabilities, management reviews the current results of the acquired business, along with projected results for the remaining earn-out period, to calculate the expected earn-out payment to be made based on the contractual terms set out in the respective acquisition agreement. The Acurity and Nexera earn-out liability utilized a credit spread of 1.0% at March 31, 2021 and June 30, 2020. As of March 31, 2021 and June 30, 2020, the undiscounted range of outcomes is between $0 and $30.0 million. A significant decrease in the probability could result in a significant decrease in the value of the earn-out liability. The fair value of the Acurity and Nexera earn-out liability at March 31, 2021 and June 30, 2020 was $24.0 million and $22.7 million, respectively.

20

Acurity and Nexera Earn-out (a)

Input assumptions	As of March 31, 2021		As of June 30, 2020
Probability of transferred member renewal percentage < 50%	5.0	%	5.0	%
Probability of transferred member renewal percentage between 50% and 65%	10.0	%	10.0	%
Probability of transferred member renewal percentage between 65% and 80%	25.0	%	25.0	%
Probability of transferred member renewal percentage > 80%	60.0	%	60.0	%
Credit spread	1.0	%	1.0	%

(a)    The Acurity and Nexera earn-out liability was initially valued as of February 28, 2020.

A reconciliation of the Company’s FFF put and call rights and earn-out liabilities is as follows (in thousands):

	Beginning Balance		Purchases (Settlements) (a)		Gain (Loss) (b)		Ending Balance
Three Months Ended March 31, 2021
Earn-out liabilities	$	22,700	—		(1,254)		23,954
FFF put right	53,184		—		(5,195)		58,379
Total Level 3 liabilities	$	75,884	$	—	$	(6,449)	$	82,333
Three Months Ended March 31, 2020
Earn-out liabilities	$	13,420	$	22,700	$	1,233	$	34,887
FFF put right	19,065		—		(13,906)		32,971
Total Level 3 liabilities	$	32,485	$	22,700	$	(12,673)	$	67,858
Nine Months Ended March 31, 2021
Earn-out liabilities	$	33,151	$	(13,733)	$	(4,536)	$	23,954
FFF put right	36,758		—		(21,621)		58,379
Total Level 3 liabilities	$	69,909	$	(13,733)	$	(26,157)	$	82,333
Nine Months Ended March 31, 2020
FFF call right	$	204	$	—	$	(204)	$	—
Total Level 3 assets	204		—		(204)		—
Earn-out liabilities	6,816		26,481		(1,590)		34,887
FFF put right	41,652		—		8,681		32,971
Total Level 3 liabilities	$	48,468	$	26,481	$	7,091	$	67,858

(a)    Purchases (Settlements) for the nine months ended March 31, 2021 includes the Medpricer earnout, which has been earned in part but not yet paid as of March 31, 2021 and the Stanson earnout, which was paid in full as of December 31, 2020.

(b)    A gain on level 3 asset balances will increase the asset ending balance whereby a gain on level 3 liability balances will decrease the liability ending balance. A loss on level 3 asset balances will decrease the asset ending balance whereby a loss on level 3 liability balance will increase the liability ending balance.

Non-Recurring Fair Value Measurements

During the nine months ended March 31, 2021, the Company recorded notes payable to members resulting from the deferral of the early termination payments associated with the termination of the TRA as part of the August 2020 restructuring. These notes include a Level 2 input associated with the implied interest rate of 1.8% and are calculated as of August 11, 2020. (see Note 9 - Debt and Notes Payable).

During the nine months ended March 31, 2021, no non-recurring fair value measurements were required relating to the measurement of goodwill and intangible assets for impairment. However, purchase price allocations required significant non-recurring Level 3 inputs. The preliminary fair values of the acquired intangible assets resulting from the IDS Acquisition was determined using the income approach (see Note 3 - Business Acquisitions).

21

Financial Instruments For Which Fair Value Only is Disclosed

The fair values of non-interest bearing notes payable, classified as Level 2, were less than their carrying value by $0.2 million at March 31, 2021 and June 30, 2020, based on assumed market interest rates of 1.6% for both periods.

Other Financial Instruments

The fair values of cash, accounts receivable, accounts payable, accrued liabilities, and the Credit Facility (as defined in Note 9 - Debt and Notes Payable) approximated carrying value due to the short-term nature of these financial instruments.

(7) CONTRACT BALANCES

Deferred Revenue

Revenue recognized during the nine months ended March 31, 2021 that was included in the opening balance of deferred revenue at June 30, 2020 was $16.5 million, which is a result of satisfying performance obligations.

Performance Obligations

A performance obligation is a promise to transfer a distinct good or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Contracts may have a single performance obligation as the promise to transfer individual goods or services is not separately identifiable from other promises and, therefore, not distinct, while other contracts may have multiple performance obligations, most commonly due to the contract covering multiple phases or deliverable arrangements (licensing fees, implementation fees, maintenance and support fees, professional fees for consulting services), including certain performance guarantees.

Net revenue recognized during the three months ended March 31, 2021 from performance obligations that were satisfied or partially satisfied in prior periods was $8.5 million. The net revenue recognized was driven by a $11.4 million increase in net administrative fees revenue related to under-forecasted cash receipts received in the current period partially offset by a reduction of $2.9 million associated with revised forecasts from underlying contracts that include variable consideration components as well as additional fluctuations due to input method contracts which occur in the normal course of business.

The reduction to net revenue recognized during the nine months ended March 31, 2021 from performance obligations that were satisfied or partially satisfied in prior periods was $3.9 million. The reduction was driven by a $0.9 million decrease in net administrative fees revenue related to over-forecasted cash receipts received in the current period and a reduction of $3.0 million associated with revised forecasts from underlying contracts that include variable consideration components as well as additional fluctuations due to input method contracts which occur in the normal course of business.

Reduction in net revenue recognized during the three and nine months ended March 31, 2020 from performance obligations that were satisfied or partially satisfied in prior periods was $0.1 million and $1.4 million, respectively. The reduction was driven by $3.8 million and $6.9 million, respectively, associated with revised forecasts from underlying contracts that include variable consideration components as well as additional fluctuations due to input method contracts which occur in the normal course of business. This was offset by $3.7 million and $5.5 million, respectively, of net administrative fees revenue related to under-forecasted cash receipts received in the current period.

Remaining performance obligations represent the portion of the transaction price that has not yet been satisfied or achieved. As of March 31, 2021, the aggregate amount of the transaction price allocated to remaining performance obligations was $589.5 million. The Company expects to recognize approximately 45% of the remaining performance obligations over the next 12 months and an additional 26% over the following 12 months, with the remainder recognized thereafter.

22

(8) GOODWILL AND INTANGIBLE ASSETS

Goodwill

Goodwill consisted of the following (in thousands):

	Supply Chain Services		Performance Services		Total
June 30, 2020	$	387,722	$	554,243	$	941,965
Acquisition of businesses and assets	—		57,514		57,514
Adjustments to acquisition purchase price	780		(482)		298
March 31, 2021	$	388,502	$	611,275	$	999,777

The initial purchase price allocation for the IDS Acquisition is preliminary and subject to changes in fair value of working capital and valuation of the assets acquired and the liabilities assumed.

Adjustments to acquisition purchase price since June 30, 2020 are a result of measurement period adjustments from the Acurity and Nexera asset acquisition and the HDP acquisition. See Note 3 - Business Acquisitions for more information.

Intangible Assets, Net

Intangible assets, net consisted of the following (in thousands):

	Useful Life	March 31, 2021		June 30, 2020
Member relationships	14.7 years	$	386,100	$	386,100
Technology	6.1 years	186,017		164,117
Customer relationships	9.6 years	70,830		70,830
Trade names	7.4 years	24,610		24,160
Non-compete agreements	5.3 years	11,315		11,315
Other (a)	10.2 years	7,682		6,060
Total intangible assets		686,554		662,582
Accumulated amortization		(279,023)		(245,160)
Total intangible assets, net		$	407,531	$	417,422

(a) Includes a $1.0 million indefinite-lived asset that was acquired through the HDP acquisition.

Total intangible assets increased due to the IDS Acquisition (see Note 3 - Business Acquisitions). Intangible asset amortization was $10.4 million and $14.0 million for the three months ended March 31, 2021 and 2020, respectively, and $33.9 million and $38.9 million for the nine months ended March 31, 2021 and 2020, respectively.

(9) DEBT AND NOTES PAYABLE

Long-term debt and notes payable consisted of the following (in thousands):

	March 31, 2021		June 30, 2020
Credit Facility	$	200,000	$	75,000
Notes payable to members	418,639		—
Other notes payable	9,297		9,200
Total debt and notes payable	627,936		84,200
Less: current portion	(299,447)		(79,560)
Total long-term debt and notes payable	$	328,489	$	4,640

Credit Facility

Premier LP, along with its consolidated subsidiaries, PSCI and PHSI, as Co-Borrowers, Premier GP and certain domestic subsidiaries of Premier GP, as guarantors, entered into an unsecured Credit Facility, dated as of November 9, 2018 (the “Credit

23

Facility”). The Credit Facility has a maturity date of November 9, 2023, subject to up to two one-year extensions at the request of the Co-Borrowers and approval of a majority of the lenders under the Credit Facility. The Credit Facility provides for borrowings of up to $1.0 billion with (i) a $50.0 million sub-facility for standby letters of credit and (ii) a $100.0 million sub-facility for swingline loans. The Credit Facility also provides that Co-Borrowers may from time to time (i) incur incremental term loans and (ii) request an increase in the revolving commitments under the Credit Facility, together up to an aggregate of $350.0 million, subject to the approval of the lenders providing such term loans or revolving commitment increases. The Credit Facility includes an unconditional and irrevocable guaranty of all obligations under the Credit Facility by Premier GP, certain domestic subsidiaries of Premier GP and future guarantors, if any. Premier, Inc. is not a guarantor under the Credit Facility.

Outstanding borrowings under the Credit Facility bear interest on a variable rate structure with borrowings bearing interest at either London Interbank Offered Rate (“LIBOR”) plus an applicable margin ranging from 1.000% to 1.500% or the prime lending rate plus an applicable margin ranging from 0.000% to 0.500%. At March 31, 2021, the interest rate on outstanding borrowings under the Credit Facility was 1.115%. The Credit Facility contains customary representations and warranties as well as customary affirmative and negative covenants. Premier GP was in compliance with all such covenants at March 31, 2021. The Credit Facility also contains customary events of default, including a cross-default of any indebtedness or guarantees in excess of $75.0 million. If any event of default occurs and is continuing, the administrative agent under the Credit Facility may, with the consent, or shall, at the request of a majority of the lenders under the Credit Facility, terminate the commitments and declare all of the amounts owed under the Credit Facility to be immediately due and payable.

Proceeds from borrowings under the Credit Facility may generally be used to finance ongoing working capital requirements, including permitted acquisitions, repurchases of Class A common stock pursuant to stock repurchase programs, dividend payments, if and when declared, and other general corporate activities. During the nine months ended March 31, 2021, the Company borrowed $225.0 million and repaid $100.0 million of borrowings under the Credit Facility. The Company had $200.0 million in outstanding borrowings under the Credit Facility at March 31, 2021 with $799.9 million of available borrowing capacity after reductions for outstanding borrowings and outstanding letters of credit. In April 2021, the Company repaid $75.0 million of outstanding borrowings under the Credit Facility.

Notes Payable

Notes Payable to Members

On August 10, 2020, the Company exercised its right to terminate the TRA by and among the Company and the former limited partners of Premier LP by providing all former LPs a notice of the termination and the amount of the expected payment to be made to each LP pursuant to the early termination provisions of the TRA (each such amount an “Early Termination Payment”) with a determination date of August 10, 2020 (the “Determination Date”). The valuation of the Early Termination Payment is based on the average of the closing prices of a share of Class A common stock on the stock exchange over the 20 trading days ending three days prior to the Determination Date. The aggregate amount of the Early Termination Payments was $472.6 million. Of that amount, $10.5 million was paid on September 15, 2020, to LPs that did not elect to execute a Unit Exchange and Tax Receivable Acceleration Agreement (“Unit Exchange Agreement”) in connection with the Company’s August 2020 restructuring. The remaining amount payable, $462.1 million in the aggregate, will be paid, without interest, to certain LPs that elected to execute a Unit Exchange Agreement, which deferred the Early Termination Payments over 18 quarterly installments commencing during the quarter ended March 31, 2021 and ending in the quarter ending June 30, 2025. While non-interest bearing, pursuant to GAAP requirements, the notes payable to members were recorded net of imputed interest of 1.8%. During the quarter ended March 31, 2021, the Company paid the first quarterly installment of $25.7 million.

At March 31, 2021, the Company had $418.6 million of notes payable to members, net of discounts on notes payable of $17.8 million, of which $95.5 million was recorded to current portion of notes payable to members in the accompanying Condensed Consolidated Balance Sheets.

Other

At March 31, 2021 and June 30, 2020, the Company had $9.3 million and $9.2 million in other notes payable, respectively, of which $4.0 million and $4.6 million, respectively, were included in current portion of long-term debt in the accompanying Condensed Consolidated Balance Sheets. Other notes payable do not bear interest and generally have stated maturities of three to five years from their date of issuance.

24

Future minimum principal payments on total outstanding notes payable as of March 31, 2021 are as follows (in thousands):

2021 (a)	$	29,218
2022	105,211
2023	103,629
2024	104,231
2025	103,419
Total principal payments	$	445,708

(a)     For the period from April 1, 2021 to June 30, 2021.

(10) REDEEMABLE LIMITED PARTNERS' CAPITAL

On July 31, 2020, after the resignation of three directors affiliated with the Company’s members, the Board of Directors consisted of fifteen (15) directors, comprised of eight (8) independent directors, six (6) member-directors and the Company’s Chief Executive Officer, thus having a majority of independent directors on the Board of Directors. Since the member-directors no longer comprised a majority of the Board of Directors, as of July 31, 2020, the limited partner’s redemption feature was under the control of the Company (not the holders of Class B common units). As a result, $1.8 billion representing the fair value of redeemable limited partners’ capital at July 31, 2020 was reclassified from temporary equity in the mezzanine section of the Condensed Consolidated Balance Sheets to additional paid in capital as a component of permanent equity.

For the nine months ended March 31, 2021 and 2020, the Company recorded adjustments to the fair value of redeemable limited partners’ capital as an adjustment of redeemable limited partners’ capital to redemption amount in the accompanying Condensed Consolidated Statements of Income and Comprehensive Income in the amounts of $(26.7) million and $516.7 million, respectively. With respect to the nine months ended March 31, 2021, no adjustments to the fair value of redeemable limited partners’ capital as an adjustment of redeemable limited partners’ capital to redemption amount were recorded subsequent to July 31, 2020 in the accompanying Condensed Consolidated Statements of Income and Comprehensive Income. Refer to “Company Structure and Restructuring” in Note 1 - Organization and Basis of Presentation.

The tables below provide a summary of the changes in redeemable limited partners’ capital from June 30, 2020 to September 30, 2020 and June 30, 2019 to March 31, 2020 (in thousands). There were no changes in redeemable limited partner’s capital from September 30, 2020 to March 31, 2021.

	Receivables From Limited Partners		Redeemable Limited Partners' Capital		Total Redeemable Limited Partners' Capital
June 30, 2020	$	(995)	$	1,721,304	$	1,720,309
Distributions applied to receivables from limited partners	141		—		141
Net income attributable to non-controlling interest in Premier LP	—		11,845		11,845
Distributions to limited partners	—		(1,936)		(1,936)
Exchange of Class B common units for Class A common stock by member owners	—		(2,437)		(2,437)
Adjustment of redeemable limited partners' capital to redemption amount	—		26,685		26,685
Reclassification to permanent equity	854		(1,755,461)		(1,754,607)
September 30, 2020	$	—	$	—	$	—

25

	Receivables From Limited Partners		Redeemable Limited Partners’ Capital		Total Redeemable Limited Partners’ Capital
June 30, 2019	$	(1,204)	$	2,524,474	$	2,523,270
Distributions applied to receivables from limited partners	69		—		69
Redemption of limited partners	—		(1,371)		(1,371)
Net income attributable to non-controlling interest in Premier LP	—		41,907		41,907
Distributions to limited partners	—		(13,699)		(13,699)
Exchange of Class B common units for Class A common stock by member owners	—		(50,792)		(50,792)
Adjustment of redeemable limited partners' capital to redemption amount	—		(694,309)		(694,309)
September 30, 2019	(1,135)		1,806,210		1,805,075
Distributions applied to receivables from limited partners	70		—		70
Net income attributable to non-controlling interest in Premier LP	—		55,704		55,704
Distributions to limited partners	—		(12,689)		(12,689)
Exchange of Class B common units for Class A common stock by member owners	—		(223,946)		(223,946)
Adjustment of redeemable limited partners' capital to redemption amount	—		480,153		480,153
December 31, 2019	(1,065)		2,105,432		2,104,367
Distributions applied to receivables from limited partners	71		—		71
Net income attributable to non-controlling interest in Premier LP	—		35,058		35,058
Distributions to limited partners	—		(9,314)		(9,314)
Exchange of Class B common units for Class A common stock by member owners	—		(169,194)		(169,194)
Adjustment of redeemable limited partners' capital to redemption amount	—		(302,569)		(302,569)
March 31, 2020	$	(994)	$	1,659,413	$	1,658,419

Pursuant to the Exchange Agreement in place prior to the August 2020 restructuring, each limited partner had the cumulative right to exchange up to one-seventh of its initial allocation of Class B common units for shares of Class A common stock, cash or a combination of both, the form of consideration to be at the discretion of the Company's independent Audit and Compliance Committee of the Board of Directors. During the nine months ended March 31, 2021, the Company recorded total reductions of $2.4 million to redeemable limited partners' capital prior to the August 2020 restructuring to reflect the exchange of 0.1 million Class B common units and surrender and retirement of a corresponding number of shares of Class B common stock by member owners for a like number of shares of the Company's Class A common stock (see Note 12 - Earnings Per Share for more information). On August 11, 2020, the Exchange Agreement was terminated in connection with the restructuring as discussed in Note 1 - Organization and Basis of Presentation.

Quarterly exchanges during the nine months ended March 31, 2021 were as follows (in thousands, except Class B common units):

Date of Quarterly Exchange	Number of Class B Common Units Exchanged	Reduction in Redeemable Limited Partners' Capital
July 31, 2020	69,684	$	2,437

As a result of the August 2020 restructuring, there were no quarterly exchanges subsequent to the July 31, 2020 exchange.

(11) STOCKHOLDERS' EQUITY

As of March 31, 2021, there were 122,268,758 shares of the Company's Class A common stock, par value $0.01 per share, outstanding.

Holders of Class A common stock are entitled to (i) one vote for each share held of record on all matters submitted to a vote of stockholders, (ii) receive dividends, when and if declared by the Board of Directors out of funds legally available, subject to any statutory or contractual restrictions on the payment of dividends and subject to any restrictions on the payment of dividends

26

imposed by the terms of any outstanding preferred stock or any class of series of stock having a preference over or the right to participate with the Class A common stock with respect to the payment of dividends or other distributions and (iii) receive pro rata, based on the number of shares of Class A common stock held, the remaining assets available for distribution upon the dissolution or liquidation of Premier, after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any.

On July 31, 2020, $1.8 billion representing the fair value of redeemable limited partners capital on July 31, 2020 was reclassified from temporary equity in the mezzanine section of the Condensed Consolidated Balance Sheets to additional paid in capital as a component of permanent equity. Refer to Note 10 - Redeemable Limited Partners' Capital for further discussion.

On August 11, 2020, pursuant to the Merger Agreement, each of the issued and outstanding Class B common units was canceled and converted automatically into a right to receive one share of the Company’s Class A common stock. In conjunction with the Merger, all of the issued and outstanding shares of Class B common stock of the Company beneficially held by the LPs were canceled in accordance with the Company’s Certificate of Incorporation. On August 11, 2020, the Company issued 50,143,414 shares of Class A common stock pursuant to the Merger.

On September 15, 2020, December 15, 2020, and March 15, 2021, the Company paid a cash dividend of $0.19 per share on outstanding shares of Class A common stock to stockholders of record on September 1, 2020, December 1, 2020, and March 1, 2021, respectively. On April 23, 2021, the Board of Directors declared a cash dividend of $0.19 per share, payable on June 15, 2021 to stockholders of record on June 1, 2021.

(12) EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income attributable to stockholders by the weighted average number of shares of common stock outstanding for the period. Net income attributable to stockholders includes the adjustment recorded in the period to reflect redeemable limited partners’ capital at the redemption amount, which is due to the exchange benefit obtained by limited partners through the ownership of Class B common units. Except when the effect would be anti-dilutive, the diluted earnings (loss) per share calculation, which is calculated using the treasury stock method, includes the impact of shares that could be issued under the outstanding stock options, non-vested restricted stock units and awards, shares of non-vested performance share awards and the effect of the assumed redemption of Class B common units through the issuance of Class A common shares.

On August 11, 2020, pursuant to the Merger Agreement, each of the issued and outstanding Class B common units (and corresponding shares of the Company’s Class B common stock) was canceled and converted automatically into a right to receive one share of the Company’s Class A common stock, and the Company issued an aggregate of 50,143,414 shares of Class A common stock. Refer to Note 1 - Organization and Basis of Presentation for further discussion.

The following table provides a reconciliation of the numerator and denominator used for basic and diluted (loss) earnings per share (in thousands, except per share amounts):

	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Numerator for basic earnings per share:
Net income from continuing operations attributable to stockholders (a)	$	48,321	$	340,726	$	234,445	$	620,262
Net income from discontinued operations attributable to stockholders	—		2		—		529
Net income attributable to stockholders	$	48,321	$	340,728	$	234,445	$	620,791
Numerator for diluted earnings per share:
Net income from continuing operations attributable to stockholders (a)	$	48,321	$	340,726	$	234,445	$	620,262
Adjustment of redeemable limited partners’ capital to redemption amount	—		(302,569)		—		(516,725)
Net income from continuing operations attributable to non-controlling interest in Premier LP	—		35,055		—		132,189
Net income from continuing operations	48,321		73,212		234,445		235,726
Tax effect on Premier, Inc. net income (b)(c)	—		(7,067)		—		(30,007)
Adjusted net income from continuing operations	$	48,321	$	66,145	$	234,445	$	205,719

27

	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Net income from discontinued operations attributable to stockholders	$	—	$	2	$	—	$	529
Net income from discontinued operations attributable to non-controlling interest in Premier LP	—		3		—		480
Adjusted net income from discontinued operations	$	—	$	5	$	—	$	1,009
Adjusted net income	$	48,321	$	66,150	$	234,445	$	206,728
Denominator for earnings per share:
Basic weighted average shares outstanding (d)	122,254		69,451		114,596		65,582
Effect of dilutive securities: (e)
Stock options	325		232		300		357
Restricted stock	373		216		336		239
Performance share awards	164		197		133		66
Class B shares outstanding	—		52,374		—		57,786
Diluted weighted average shares and assumed conversions	123,116		122,470		115,365		124,030
Earnings per share attributable to stockholders:
Basic earnings per share attributable to stockholders	$	0.40	$	4.91	$	2.05	$	9.47
Diluted earnings per share attributable to stockholders	$	0.39	$	0.54	$	2.03	$	1.66

(a)Net income from continuing operations attributable to stockholders was calculated as follows (in thousands):

	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Net income from continuing operations	$	51,444	$	73,212	$	277,033	$	235,726
Net income from continuing operations attributable to non-controlling interest	(3,123)		(35,055)		(15,903)		(132,189)
Adjustment of redeemable limited partners’ capital to redemption amount	—		302,569		(26,685)		516,725
Net income from continuing operations attributable to stockholders	$	48,321	$	340,726	$	234,445	$	620,262

(b)For the three months ended March 31, 2021, the tax expense related to Premier, Inc. retaining the portion of net income from continuing operations attributable to income from non-controlling interest in PRAM and DePre Holdings, LLC (“DPH”) was calculated as a component of the income tax provision for the three months ended March 31, 2021.

(c)For the nine months ended March 31, 2021, the tax expense related to Premier, Inc. retaining the portion of net income from continuing operations attributable to income from non-controlling interest in Premier, LP, PRAM and DPH was calculated as a component of the income tax provision for the nine months ended March 31, 2021.

(d)For the three and nine months ended March 31, 2020, represents income tax expense related to Premier, Inc. retaining the portion of net income from continuing operations attributable to income from non-controlling interest in Premier, LP for the purpose of diluted earnings per share.

(e)Weighted average number of common shares used for basic earnings per share excludes weighted average shares of non-vested stock options, non-vested restricted stock, non-vested performance share awards and Class B shares outstanding for the three and nine months ended March 31, 2021 and 2020.

(f)For the three months ended March 31, 2021, the effect of 0.4 million stock options and restricted stock units were excluded from diluted weighted average shares outstanding as they had an anti-dilutive effect.

For the nine months ended March 31, 2021, the effect of 1.5 million stock options and restricted stock units and 7.5 million Class B common units were excluded from diluted weighted average shares outstanding as they had an anti-dilutive effect.

For the three and nine months ended March 31, 2021, the effect of 0.7 million performance share awards was excluded from diluted weighted average shares outstanding as the awards had not satisfied the applicable performance criteria at the end of the period.

For the three and nine months ended March 31, 2020, the effect of 0.8 million stock options and restricted stock units was excluded from diluted weighted average shares outstanding as they had an anti-dilutive effect. Additionally, the effect of less than 0.1 million performance share awards was excluded from diluted weighted average shares outstanding as the awards had not satisfied the applicable performance criteria at the end of the period.

Pursuant to the Exchange Agreement in place prior to the August 2020 restructuring, on a quarterly basis, the Company had the option, as determined by the Audit and Compliance Committee, to settle the exchange of Class B common units of Premier LP by member owners for cash, an equal number of Class A common shares of Premier, Inc. or a combination of cash and shares

28

of Class A common stock. In connection with the exchange of Class B common units by member owners, regardless of the consideration used to settle the exchange, an equal number of shares of Premier's Class B common stock were surrendered by member owners and retired (see Note 10 - Redeemable Limited Partners' Capital). On August 11, 2020, the Exchange Agreement was terminated in connection with the restructuring as discussed in Note 1 - Organization and Basis of Presentation.

The following table presents certain information regarding the exchange of Class B common units and associated Class B common stock for Premier's Class A common stock and/or cash in connection with the quarterly exchange pursuant to the terms of the Exchange Agreement, including activity related to the Class A and Class B common units and Class A and Class B common stock through the date of the applicable quarterly exchange:

Quarterly Exchange by Member Owners	Class B Common Shares Retired Upon Exchange (a)	Class B Common Shares Outstanding After Exchange (a)	Class A Common Shares Outstanding After Exchange (b)	Percentage of Combined Voting Power Class B/Class A Common Stock
July 31, 2020	69,684	50,143,414	71,724,149	41%/59%

(a)The number of Class B common shares retired or outstanding is equivalent to the number of Class B common units retired upon exchange or outstanding after the exchange, as applicable.

(b)The number of Class A common shares outstanding after exchange also includes activity related to the Company's share repurchase program equity incentive plan (see Note 13 - Stock-Based Compensation).

(13) STOCK-BASED COMPENSATION

Stock-based compensation expense is recognized over the requisite service period, which generally equals the stated vesting period. The associated deferred tax benefit was calculated at a rate of 26% for the three months ended March 31, 2021 and 25% for the three months ended March 31, 2020, which represents the expected effective income tax rate at the time of the compensation expense deduction and differs from the Company’s current effective income tax rate which includes the impact of the Merger. See Note 14 - Income Taxes for further information.

Stock-based compensation expense and the resulting deferred tax benefits were as follows (in thousands):

	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Pre-tax stock-based compensation expense	$	13,056	$	7,568	$	27,601	$	19,048
Deferred tax benefit (a)	2,521		1,915		4,641		4,819
Total stock-based compensation expense, net of tax	$	10,535	$	5,653	$	22,960	$	14,229

(a) For the three and nine months ended March 31, 2021, the deferred tax benefit was reduced by $0.9 million and 2.5 million, respectively, attributable to stock-based compensation expense that is nondeductible for tax purposes pursuant to Section 162(m) as amended by the Tax Cuts and Jobs Act of 2017.

Premier 2013 Equity Incentive Plan

The Premier 2013 Equity Incentive Plan, as amended and restated (and including any further amendments thereto, the “2013 Equity Incentive Plan”) provides for grants of up to 14.8 million shares of Class A common stock, all of which are eligible to be issued as non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock, restricted stock units or performance share awards. As of March 31, 2021, there were 5.3 million shares available for grant under the 2013 Equity Incentive Plan.

29

The following table includes information related to restricted stock, performance share awards and stock options for the nine months ended March 31, 2021:

	Restricted Stock			Performance Share Awards			Stock Options
	Number of Awards	Weighted Average Fair Value at Grant Date		Number of Awards	Weighted Average Fair Value at Grant Date		Number of Options	Weighted Average Exercise Price
Outstanding at June 30, 2020	681,538	$	37.91	1,606,309	$	37.58	2,544,137	$	30.17
Granted	571,761	$	31.94	695,233	$	29.20	—	$	—
Vested/exercised	(200,384)	$	34.40	(161,544)	$	32.77	(124,390)	$	30.96
Forfeited	(57,813)	$	36.26	(401,425)	$	33.71	(33,184)	$	35.13
Outstanding at March 31, 2021	995,102	$	35.28	1,738,573	$	35.57	2,386,563	$	30.05
Stock options outstanding and exercisable at March 31, 2021							2,386,563	$	30.05

Restricted stock units and restricted stock awards issued and outstanding generally vest over a three-year period for employees and a one-year period for directors. Performance share awards issued and outstanding generally vest over a three-year period if performance targets are met. Stock options have a term of ten years from the date of grant. Vested stock options will expire either twelve months after an employee’s termination with Premier or immediately upon an employee’s termination with Premier, depending on the termination circumstances. Stock options generally vest in equal annual installments over three years.

Unrecognized stock-based compensation expense at March 31, 2021 was as follows (in thousands):

	Unrecognized Stock-Based Compensation Expense		Weighted Average Amortization Period
Restricted stock	$	19,926	2.0 years
Performance share awards	27,191		1.8 years
Total unrecognized stock-based compensation expense	$	47,117	1.9 years

The aggregate intrinsic value of stock options at March 31, 2021 was as follows (in thousands):

	Intrinsic Value of Stock Options
Outstanding and exercisable	$	9,757
Expected to vest	—
Total outstanding	$	9,757
Exercised during the year ended March 31, 2021	527

(14) INCOME TAXES

On August 11, 2020, the Company entered into the Merger Agreement and pursuant to the Merger Agreement, each of the issued and outstanding Class B common units was canceled and converted automatically into a right to receive one share of the Company’s Class A common stock. In conjunction with the Merger, all the issued and outstanding shares of Class B common stock of the Company beneficially held by the LPs were canceled in accordance with the Company’s Certificate of Incorporation.

At the consummation of the Merger, the Company simplified its tax structure, resulting in the Company and its subsidiaries forming one consolidated filing group for tax purposes. As a result, the Company recorded a one-time deferred tax benefit of $131.4 million, primarily driven by deferred tax remeasurement due to the change in the state statutory rate and valuation allowance release.

30

Income tax expense for the three months ended March 31, 2021 and 2020 was $13.4 million and $4.2 million, respectively, which reflects effective tax rates of 21% and 5%, respectively. The effective tax rate for the three months ended March 31, 2021 increased compared to the prior year period as a result of the prior year impact of the income tax benefit associated with the NOL carryback provisions under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) and the associated release of the valuation allowance in March 2020. Income tax (benefit) expense for the nine months ended March 31, 2021 and 2020 was $(88.0) million and $78.3 million, respectively, which reflects effective tax rates of (47)% and 25%, respectively. The change in the effective tax rate for the nine months ended March 31, 2021 is primarily driven by the aforementioned one-time deferred tax remeasurement and valuation allowance release as a result of the Merger. Excluding the one-time deferred tax benefit, the effective tax rate would have been 23% for the nine months ended March 31, 2021.

Net deferred tax assets increased by $408.9 million to $821.4 million at March 31, 2021 from $412.5 million at June 30, 2020. The increase in net deferred tax assets was largely driven by an increase of $285.0 million in deferred tax assets related to the final exchange of all outstanding Class B common units for the Company’s Class A common stock on August 11, 2020 and $131.4 million deferred tax remeasurement and valuation allowance release as a result of the Merger.

On August 10, 2020, the Company exercised its right to terminate the TRA by and among the Company and the former limited partners of Premier LP by providing all former LPs a notice of the termination and the amount of the expected payment to be made to each LP pursuant to the early termination provisions of the TRA on the Determination Date (see Note 9 - Debt and Notes Payable for further information). As a result of the TRA termination, TRA liabilities of $293.7 million at June 30, 2020 were extinguished and a liability was recorded to current portion of notes payable to members and notes payable to members, less current portion in the accompanying Condensed Consolidated Balance Sheets for amounts payable pursuant to the Unit Exchange Agreements.

(15) RELATED PARTY TRANSACTIONS

The Company’s 49% ownership share of net income of FFF, which was acquired on July 26, 2016, included in equity in net income of unconsolidated affiliates in the accompanying Condensed Consolidated Statements of Income and Comprehensive Income was $0.8 million and $4.3 million for the three months ended March 31, 2021 and 2020, respectively, and $8.4 million and $10.8 million for the nine months ended March 31, 2021 and 2020, respectively. The Company maintains group purchasing agreements with FFF and receives administrative fees for purchases made by the Company’s members and other customers pursuant to those agreements. Net administrative fees revenue recorded from purchases under those agreements was $1.1 million and $1.2 million during the three months ended March 31, 2021 and 2020, respectively, and $4.6 million and $5.8 million for the nine months ended March 31, 2021 and 2020.

(16) COMMITMENTS AND CONTINGENCIES

Operating Leases

Operating lease expense for the three months ended March 31, 2021 and 2020 was $2.6 million and $2.7 million, respectively. Operating lease expense for the nine months ended March 31, 2021 and 2020 were both $8.2 million. As of March 31, 2021, the weighted average remaining lease term was 5.0 years and the weighted average discount rate was 4%.

Future minimum lease payments under noncancelable operating leases with initial lease terms in excess of one year were as follows (in thousands):

	March 31, 2021		June 30, 2020
2021 (a)	$	2,995	$	12,171
2022	11,738		11,738
2023	12,012		12,012
2024	12,145		12,145
2025	12,177		12,177
Thereafter	10,171		10,171
Total future minimum lease payments	61,238		70,414
Less: imputed interest	5,820		7,567
Total operating lease liabilities (b)	$	55,418	$	62,847

(a)As of March 31, 2021, future minimum lease payments are for the period from April 1, 2021 to June 30, 2021.

(b)As of March 31, 2021, total operating lease liabilities included $9.8 million within other liabilities, current in the Condensed Consolidated Balance Sheets.

31

Other Matters

The Company is not currently involved in any litigation it believes to be material. The Company is periodically involved in litigation, arising in the ordinary course of business or otherwise, which from time to time may include claims relating to commercial, product liability, tort and personal injury, employment, antitrust, intellectual property, or other regulatory matters. Furthermore, as a public company, the Company may become subject to stockholder derivative or other similar litigation. If current or future government regulations, specifically, those with respect to antitrust or healthcare laws, are interpreted or enforced in a manner adverse to the Company or its business, the Company may be subject to enforcement actions, penalties and other material limitations which could have a material adverse effect on the Company’s business, financial condition and results of operations.

(17) SEGMENTS

The Company delivers its solutions and manages its business through two reportable business segments, the Supply Chain Services segment and the Performance Services segment. The Supply Chain Services segment includes the Company’s GPO, supply chain co-management and direct sourcing activities. The Performance Services segment includes the Company’s informatics, collaborative, consulting services, direct-to-employer initiative and insurance management services businesses.

The following table presents disaggregated revenue by business segment and underlying source (in thousands):

	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Net revenue:
Supply Chain Services
Net administrative fees	$	146,553	$	174,049	$	424,537	$	518,566
Other services and support	8,630		3,396		18,307		8,439
Services	155,183		177,445		442,844		527,005
Products	215,995		61,183		511,080		167,344
Total Supply Chain Services (a)	371,178		238,628		953,924		694,349
Performance Services (a)	98,745		96,195		285,713		262,490
Net revenue	$	469,923	$	334,823	$	1,239,637	$	956,839

(a)Includes intersegment revenue that is eliminated in consolidation. Intersegment revenue is not separately identified in Segments as the amounts are not material.

32

Additional segment information related to depreciation and amortization expense, capital expenditures and total assets was as follows (in thousands):

	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Depreciation and amortization expense (a):
Supply Chain Services	$	9,389	$	6,896	$	27,608	$	16,592
Performance Services	18,196		30,950		55,763		91,862
Corporate	2,152		1,897		6,397		6,184
Total depreciation and amortization expense	$	29,737	$	39,743	$	89,768	$	114,638
Capital expenditures:
Supply Chain Services	$	2,486	$	2,485	$	8,061	$	4,571
Performance Services	18,835		20,840		54,118		57,956
Corporate	726		1,233		4,732		6,799
Total capital expenditures	$	22,047	$	24,558	$	66,911	$	69,326

	March 31, 2021		June 30, 2020
Total assets:
Supply Chain Services	$	1,698,254	$	1,483,751
Performance Services	1,043,065		930,968
Corporate	940,706		538,248
Total assets	3,682,025		2,952,967
Eliminations (b)	(60)		(4,452)
Total assets, net	$	3,681,965	$	2,948,515

(a)Includes amortization of purchased intangible assets.

(b)Includes eliminations of intersegment transactions which occur during the ordinary course of business.

The Company uses Segment Adjusted EBITDA (a financial measure not determined in accordance with generally accepted accounting principles (“Non-GAAP”)) as its primary measure of profit or loss to assess segment performance and to determine the allocation of resources. The Company also uses Segment Adjusted EBITDA to facilitate the comparison of the segment operating performance on a consistent basis from period to period. The Company defines Segment Adjusted EBITDA as the segment’s net revenue and equity in net income of unconsolidated affiliates less operating expenses directly attributable to the segment excluding depreciation and amortization, amortization of purchased intangible assets, merger and acquisition related expenses and non-recurring or non-cash items. Operating expenses directly attributable to the segment include expenses associated with sales and marketing, general and administrative and product development activities specific to the operation of each segment. Non-recurring items are income or expenses and other items that have not been earned or incurred within the prior two years and are not expected to recur within the next two years. General and administrative corporate expenses that are not specific to a particular segment are not included in the calculation of Segment Adjusted EBITDA. Segment Adjusted EBITDA also excludes any income and expense that has been classified as discontinued operations.

For more information on Segment Adjusted EBITDA and the use of Non-GAAP financial measures, see “Our Use of Non-GAAP Financial Measures” within Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations.

33

A reconciliation of income before income taxes to Segment Adjusted EBITDA is as follows (in thousands):

	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Income before income taxes	$	64,888	$	77,377	$	188,996	$	314,062
Equity in net income of unconsolidated affiliates (a)	(5,524)		(4,442)		(16,023)		(11,038)
Interest and investment loss, net	3,225		9,966		8,742		9,849
Loss (gain) on FFF put and call rights (b)	5,195		13,906		21,621		(8,477)
Other (income) expense	(1,594)		5,005		(10,167)		1,996
Operating income	66,190		101,812		193,169		306,392
Depreciation and amortization	19,337		25,777		55,904		75,690
Amortization of purchased intangible assets	10,400		13,966		33,864		38,948
Stock-based compensation (c)	13,180		7,668		27,970		19,358
Acquisition and disposition related expenses	4,126		7,287		14,889		16,263
Remeasurement of tax receivable agreement liabilities (d)	—		(902)		—		(24,584)
Equity in net income of unconsolidated affiliates (a)	5,524		4,442		16,023		11,038
Deferred compensation plan income (expense) (e)	1,521		(5,476)		9,231		(2,484)
Other expense, net	929		1,315		5,718		3,929
Non-GAAP Adjusted EBITDA	$	121,207	$	155,889	$	356,768	$	444,550
Segment Non-GAAP Adjusted EBITDA:
Supply Chain Services (f)	$	117,949	$	149,212	$	339,538	$	447,081
Performance Services (f)	35,950		34,634		109,675		84,977
Corporate	(32,692)		(27,957)		(92,445)		(87,508)
Non-GAAP Adjusted EBITDA	$	121,207	$	155,889	$	356,768	$	444,550

(a)Refer to Note 5 - Investments for more information.

(b)Refer to Note 6 - Fair Value Measurements for more information.

(c)Includes non-cash employee stock-based compensation expense and stock purchase plan expense of $0.1 million during both of the three months ended March 31, 2021 and 2020. Also includes $0.4 million and $0.3 million during the nine months ended March 31, 2021 and 2020, respectively.

(d)The adjustments to TRA liabilities for the three and nine months ended March 31, 2020 is primarily attributable to decreases in the Premier, Inc. effective tax rate related to state tax liabilities.

(e)Represents realized and unrealized gains and losses and dividend income on deferred compensation plan assets.

(f)Includes intersegment revenue which is eliminated in consolidation.

34

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report. This discussion is designed to provide the reader with information that will assist in understanding our condensed consolidated financial statements, the changes in certain key items in those financial statements from quarter to quarter, and the primary factors that accounted for those changes, as well as how certain accounting principles affect our condensed consolidated financial statements. In addition, the following discussion includes certain forward-looking statements. For a discussion of important factors, including the continuing development of our business and other factors which could cause actual results to differ materially from the results referred to in the forward-looking statements, see the discussions under “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” herein and in our Form 10-K for the fiscal year ended June 30, 2020 (the “2020 Annual Report”), filed with the Securities and Exchange Commission (“SEC”).

Business Overview

Our Business

Premier, Inc. (“Premier”, the “Company”, “we”, or “our”) is a leading healthcare improvement company, uniting an alliance of more than 4,100 U.S. hospitals and health systems and approximately 200,000 other providers and organizations to transform healthcare. We partner with hospitals, health systems, physicians and other healthcare providers with the common goal of improving and innovating in the clinical, financial and operational areas of their businesses to meet the demands of a rapidly evolving healthcare industry. We deliver value through a comprehensive technology-enabled platform that offers critical supply chain services, clinical, financial, operational and value-based care software-as-a-service (“SaaS”) and licensed-based clinical analytics products, consulting services and performance improvement collaborative programs. We also provide services to non-healthcare businesses.

We generated net revenue, net income from continuing operations and Adjusted EBITDA (a financial measure not determined in accordance with generally accepted accounting principles (“Non-GAAP”)) for the periods presented as follows (in thousands):

	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Net revenue	$	469,923	$	334,823	$	1,239,637	$	956,839
Net income from continuing operations	$	51,444	$	73,212	$	277,033	$	235,726
Non-GAAP Adjusted EBITDA	$	121,207	$	155,889	$	356,768	$	444,550

See “Our Use of Non-GAAP Financial Measures” and “Results of Operations” below for a discussion of our use of Non-GAAP Adjusted EBITDA and a reconciliation of net income from continuing operations to Non-GAAP Adjusted EBITDA.

Our Business Segments

Our business model and solutions are designed to provide our members and other customers access to scale efficiencies while focusing on optimization of information resources and cost containment, provide actionable intelligence derived from anonymized data in our data warehouse provided by our members, mitigate the risk of innovation and disseminate best practices that will help our member organizations and other customers succeed in their transformation to higher quality and more cost-effective healthcare. We deliver our integrated platform of solutions that address the areas of total cost management, quality and safety improvement and population health management through two business segments: Supply Chain Services and Performance Services.

Segment net revenue for the three months ended March 31, 2021 and 2020 was as follows (in thousands):

	Three Months Ended March 31,				Change				% of Net Revenue
Net revenue:	2021		2020		2021		2020		2021		2020
Supply Chain Services	$	371,178	$	238,628	$	132,550	56	%	79	%	71	%
Performance Services	98,745		96,195		2,550		3	%	21	%	29	%
Net revenue	$	469,923	$	334,823	$	135,100	40	%	100	%	100	%

35

Segment net revenue for the nine months ended March 31, 2021 and 2020 was as follows (in thousands):

	Nine Months Ended March 31,				Change				% of Net Revenue
Net revenue:	2021		2020		2021		2020		2021		2020
Supply Chain Services	$	953,924	$	694,349	$	259,575	37	%	77	%	73	%
Performance Services	285,713		262,490		23,223		9	%	23	%	27	%
Net revenue	$	1,239,637	$	956,839	$	282,798	30	%	100	%	100	%

Our Supply Chain Services segment includes one of the largest healthcare group purchasing organization programs (“GPO”) in the United States, serving acute, non-acute, non-healthcare and alternate sites, supply chain co-management and our direct sourcing activities. We generate revenue in our Supply Chain Services segment from administrative fees received from suppliers based on the total dollar volume of supplies purchased by our members and other customers, fees from supply chain co-management and through product sales in connection with our direct sourcing activities.

Our Performance Services segment includes one of the largest clinical and cost analytics and consulting services businesses in the United States focused on healthcare providers. We are also expanding our capabilities to more fully address and coordinate care improvement and standardization in the employer, payor and life sciences markets. Our SaaS-based clinical analytics products and technology licenses utilize our comprehensive data set to provide actionable intelligence to our members and other customers, enabling them to benchmark, analyze and identify areas of improvement across three main categories: cost management, quality and safety, and value based care. The Performance Services segment also includes our technology-enabled performance improvement collaboratives, consulting services, direct to employer initiative and insurance management services.

CEO Transition

In February 2021, we announced that Susan D. DeVore is retiring on June 30, 2021 and will step down as our chief executive officer and from the Board of Directors effective May 1, 2021, and that our president, Michael J. Alkire, will become our chief executive officer and a member of the Board of Directors effective May 1, 2021. Ms. DeVore is expected to provide consulting services for a period of twenty-four (24) months after her separation.

Acquisitions

Acquisition of Invoice Delivery Services, LP Assets

On March 1, 2021, we, through a newly formed consolidated subsidiary, Premier IDS, LLC, acquired substantially all the assets and assumed certain liabilities of Invoice Delivery Services, LP (“IDS”) for an adjusted purchase price of $80.4 million, subject to certain adjustments, of which $80.0 million was paid at closing with borrowings under our Credit Facility (as defined in Note 9 - Debt and Notes Payable to the accompanying condensed financial statements).

IDS offers digitization technologies that convert paper and portable document format (“PDF”) invoices to an electronic format to automate, streamline, and simplify accounts payable processes in healthcare. IDS’ solutions include those for electronic invoicing and tracking, as well as digital payments. IDS will be integrated within Premier under the brand name RemitraTM and reported as part of the Performance Services segment. See Note 3 - Business Acquisitions to the accompanying condensed consolidated financial statements for further information.

Acquisition of Health Design Plus, LLC

On May 4, 2020, we, through our consolidated subsidiary, Premier Healthcare Solutions, Inc. (“PHSI”), acquired 97% of the equity of Health Design Plus, LLC (“HDP”) for an adjusted purchase price of $23.8 million, giving effect to certain purchase price adjustments provided for in the purchase agreement. The transaction was funded with borrowings under our Credit Facility. HDP is a third-party administrator and arranges care for employees through its Centers of Excellence program. Shortly after closing, HDP was renamed Contigo Health, LLC (“Contigo Health”) and is reported as part of the Performance Services segment. See Note 3 - Business Acquisitions to the accompanying condensed consolidated financial statements for further information.

Acquisition of Acurity and Nexera Assets

On February 28, 2020, we, through two newly formed consolidated subsidiaries, Prince A Purchaser, LLC (“PAP”) and Prince N Purchaser, LLC (“PNP”), acquired substantially all of the assets and certain liabilities of Acurity, Inc. and Nexera, Inc., both indirect wholly owned subsidiaries of Greater New York Hospital Association (“GYNHA”), for an aggregate amount of $291.5 million, of which $166.1 million was paid at closing with borrowings under our Credit Facility (the “Acurity and Nexera asset acquisition”). Pursuant to the terms of the asset purchase agreement (as amended, the “Purchase Agreement”), an additional

36

$120.0 million will be paid to the sellers in four equal annual installments of $30.0 million on or about June 30, 2021, 2022, 2023 and 2024. An additional $4.7 million was paid to GNYHA during the three months ended March 31, 2021. In addition, the Purchase Agreement provides a graduated earn-out opportunity to Acurity, Inc. of up to $30.0 million based upon our achievement of a range of member renewals on terms to be agreed to by us and GNYHA based on prevailing market conditions in December 2023.

After the closing of the transaction, we changed the names of PAP and PNP to Acurity, LLC (“Acurity”) and Nexera, LLC (“Nexera”), respectively. Acurity is a regional group purchasing organization and has been a customer and strategic partner of ours for more than 24 years. Nexera is a hospital financial improvement consulting firm which partners with healthcare organizations to improve hospital and health system performance, with a significant focus on supply chain enhancement and transformation. We report the operations of Acurity and Nexera as part of the Supply Chain Services segment. See Note 3 - Business Acquisitions to the accompanying condensed consolidated financial statements for further information.

Acquisition of Medpricer

On October 28, 2019, we, through our consolidated subsidiary, Premier Supply Chain Improvement, Inc. (“PSCI”), acquired all of the outstanding capital stock in Medpricer.com, Inc. (“Medpricer”) for an adjusted purchase price of $38.5 million giving effect to certain purchase price adjustments provided for in the purchase agreement. The transaction was funded with borrowings under the Credit Facility. Medpricer is a SaaS-based provider of technology solutions that enable hospitals and other organizations to analyze, benchmark and source purchased services contracts independent of any existing GPO affiliation. During the fourth quarter of fiscal year 2020, Medpricer changed its name to Conductiv, Inc. (“Conductiv”) and is reported as part of the Supply Chain Services segment. See Note 3 - Business Acquisitions to the accompanying condensed consolidated financial statements for further information.

Market and Industry Trends and Outlook

We expect that certain trends and economic or industrywide factors will continue to affect our business, both in the short- and long-term. We have based our expectations described below on assumptions made by us and on information currently available to us. To the extent our underlying assumptions about, or interpretation of, available information prove to be incorrect, our actual results may vary materially from our expected results. See “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” in the 2020 Annual Report.

Trends in the U.S. healthcare market affect our revenues and costs in the Supply Chain Services and Performance Services segments. The trends affecting our current healthcare business include the impact of the implementation of current or future healthcare legislation, particularly the uncertainty regarding the status of the Affordable Care Act (“ACA”) and the potential for the ACA to be struck down as unconstitutional by the U.S. Supreme Court or significantly altered by Congress. Actions related to the ACA could be disruptive for Premier and our customers, impacting revenue, reporting requirements, payment reforms, shift in care to the alternate site market and increased data availability and transparency. To meet the demands of this environment, there will be increased focus on scale and cost containment and healthcare providers will need to measure and report on and bear financial risk for outcomes. Over the long-term, we believe these trends will result in increased demand for our Supply Chain Services and Performance Services solutions in the areas of cost management, quality and safety, and value-based care, however, there are uncertainties and risks that may affect the actual impact of these anticipated trends, expected demand for our services or related assumptions on our business. See “Cautionary Note Regarding Forward-Looking Statements” for more information.

COVID-19 Pandemic

In addition to the trends in the U.S. healthcare market discussed above, we face known and unknown uncertainties arising from the outbreak of the novel coronavirus (“COVID-19”) and the resulting global pandemic and financial and operational uncertainty, including its impact on the overall economy, our sales, operations and supply chains, our members and other customers, workforce and suppliers, and countries. As a result of the COVID-19 pandemic and potential future pandemic outbreaks, we face significant risks including, but not limited to:

•Changes in the demand for our products and services. We have experienced and may continue to experience uncertainty from both significant increases and decreases in demand as a result of COVID-19. There has been a significant increase in demand for personal protective equipment (“PPE”), drugs and other supplies directly related to treating and preventing the spread of COVID-19. However, either voluntarily or due to government orders or advisories, patients, hospitals and other medical facilities continue to defer some elective procedures and routine medical visits during the crisis, which created a decline in the demand for supplies and services not related to COVID-19 through the third quarter of fiscal 2021 and such lower demand is expected to continue through fiscal 2021. In addition, as a result of our members' and other customers’ focus on managing COVID-19 and its impacts, we

37

may experience uncertain demand for our consulting and other performance service engagements. Furthermore, during the COVID-19 pandemic, many of our members' non-acute or non-healthcare facilities, such as education and hospitality businesses, closed, operated on a limited or reduced basis and have delayed re-opening, and, as a result, we may see a material reduction in product sales to those facilities. The extent to which these impacts on demand will continue, and the effect that they will have on our business and operating results, will depend upon future developments that are highly uncertain and cannot be accurately predicted.

•Limited access to our members' facilities that impacts our ability to fulfill our contractual requirements. Our member hospitals and non-acute care sites have experienced reduced or limited access for non-patients, including our field teams, consultants and other professionals, and travel restrictions have impacted our employees' ability to travel to our members' facilities. The long-term continuation, or any future recurrence of these circumstances may negatively impact the ability of our employees to more effectively deliver existing or sell new products and services to our members and could affect our performance of our existing contracts.

•Materials and personnel shortages and disruptions in supply chain, including manufacturing and shipping. The global supply chain has been significantly disrupted due to stay at home orders, border closings and rapidly escalating shipping costs. Borders closings and restrictions in response to COVID-19, particularly regarding China and India, have impacted our access to products for our members and other customers. Staffing or personnel shortages due to shelter in place orders and quarantines have impacted and in the future may impact us and our members, other customers or suppliers. In addition, due to unprecedented demand during the COVID-19 pandemic, there are widespread shortages in certain product categories. In the food service line, COVID-19 related illnesses have impacted food processing suppliers and led to plant closures. If the supply chains for materials used in the products purchased by our members through our GPO or products contract manufactured through our direct sourcing business are adversely impacted by restrictions resulting from COVID-19, our supply chains may be disrupted. In addition, due to the volatility of the price and supply of products, including PPE, there is risk that we may purchase products from suppliers at that we cannot recover in the event of a potential material price decline. Failure of our suppliers, contract manufacturers, distributors, contractors and other business partners to meet their obligations to our members, other customers or to us, or significant disruptions in their ability to do so due to their own financial or operational difficulties, may adversely impact our operations.

•Requests for contract modifications, payment deferrals or exercises of force majeure clauses. We have and may continue to receive requests for contract modifications, payment waivers and deferrals, payment reductions or amended payment terms from our contract counterparties. We have and may continue to receive requests to delay service or payment on performance service contracts. In addition, we may receive requests from our suppliers for increases to their contracted prices, and such requests may be implemented in the future. In addition, several pharmacy suppliers have exercised force majeure clauses related to failure to supply clauses in their contracts with us because they are unable to obtain raw materials for manufacturing from India and China. The standard failure to supply language in our contracts contains financial penalties to suppliers if they are unable to supply products, which such suppliers may not be able to pay. In addition, we may not be able to source products from alternative suppliers on commercially reasonable terms, or at all.

•Overall economic and capital markets decline. The impact of the COVID-19 pandemic could result in a prolonged recession or depression in the United States or globally that could harm the banking system, limit demand for all products and services and cause other seen and unforeseen events and circumstances, all of which could negatively impact us. The continued spread of COVID-19 has led to and could continue to lead to severe disruption and volatility in the United States and global capital markets, which could increase our cost of capital and adversely affect our ability to access the capital markets in the future. In addition, trading prices on the public stock market, including our Class A common stock, have been highly volatile as a result of the COVID-19 pandemic.

•Managing the evolving regulatory environment. In response to COVID-19, federal, state and local governments are issuing new rules, regulations, changing reimbursement eligibility rules, orders and advisories on a regular basis. These government actions can impact us, our members and other customers and suppliers.

The ultimate impact of COVID-19, recurrences, or similar pandemics on our business, results of operations, financial condition and cash flows is dependent on future developments, including the duration of any pandemic and the related length of its impact on the United States and global economies, which are uncertain and cannot be predicted at this time. The impact of the COVID-19 pandemic, recurrences, or future similar pandemics may also exacerbate many of the other risks described in Item 1A. “Risk Factors” section of the 2020 Annual Report. Despite our efforts to manage these impacts, their ultimate impact depends on factors beyond our knowledge or control, including the duration and severity of any outbreak and actions taken to contain its spread and mitigate its public health effects. The foregoing and other continued disruptions in our business as a

38

result of COVID-19 could result in a material adverse effect on our business, results of operations, financial condition, cash flows, prospects and the trading prices of our securities in the near-term and through some or all of fiscal 2021 and beyond.

Critical Accounting Policies and Estimates

Refer to Note 1 - Organization and Basis of Presentation and Note 2 - Significant Accounting Policies to the accompanying condensed consolidated financial statements for more information related to our use of estimates in the preparation of financial statements as well as information related to material changes in our significant accounting policies that were included in our 2020 Annual Report.

New Accounting Standards

New accounting standards that we have recently adopted as well as those that have been recently issued but not yet adopted by us are included in Note 2 - Significant Accounting Policies to the accompanying condensed consolidated financial statements, which is incorporated herein by reference.

Key Components of Our Results of Operations

Net Revenue

Net revenue consists of service revenue, which includes net administrative fees revenue and other services and support revenue, and product revenue. Net administrative fees revenue consists of GPO administrative fees in our Supply Chain Services segment. Other services and support revenue consists primarily of fees generated by our Performance Services segment as discussed below. Product revenue consists of direct sourcing product sales, which are included in the Supply Chain Services segment.

Supply Chain Services

Supply Chain Services revenue consists of GPO net administrative fees (gross administrative fees received from suppliers, reduced by the amount of revenue share paid to members), supply chain co-management and direct sourcing revenue.

The success of our Supply Chain Services revenue streams are influenced by our ability to negotiate favorable contracts with suppliers and members, the number of members that utilize our GPO supplier contracts and the volume of their purchases, as well as the impact of changes in the defined allowable reimbursement amounts determined by Medicare, Medicaid and other managed care plans and the number of members and other customers that purchase products through our direct sourcing activities and the impact of competitive pricing.

Performance Services

Performance Services revenue consists of SaaS clinical analytics products subscriptions, license fees, performance improvement collaborative and other service subscriptions, professional fees for consulting services, third party administrator fees for our direct to employer initiative, insurance services management fees and commissions from endorsed commercial insurance programs.

Our Performance Services growth will depend upon the expansion of our SaaS clinical analytics products, performance improvement collaboratives and consulting services to new and existing members and other customers, renewal of existing subscriptions to our SaaS and licensed informatics products, and our ability to generate additional applied sciences engagements and expand into new markets.

Cost of Revenue

Cost of revenue consists of cost of service revenue and cost of product revenue.

Cost of service revenue includes expenses related to employees (including compensation and benefits) and outside consultants who directly provide services related to revenue-generating activities, including consulting services to members and other customers and implementation services related to SaaS clinical analytics along with associated amortization of certain capitalized contract costs. Amortization of contract costs represent amounts that have been capitalized and reflect the incremental costs of obtaining and fulfilling a contract. Amortization of contract costs included within cost of service revenue include costs related to implementing SaaS informatics tools. Cost of service revenue also includes expenses related to hosting services, related data center capacity costs, third-party product license expenses and amortization of the cost of internally developed software applications.

39

Cost of product revenue consists of purchase and shipment costs for direct sourced medical products. Our cost of product revenue is influenced by the manufacturing and transportation costs associated with direct sourced medical products.

Operating Expenses

Selling, general and administrative expenses are directly associated with selling and administrative functions and support of revenue-generating activities including expenses to support and maintain our software-related products and services. Selling, general and administrative expenses primarily consist of compensation and benefits related costs, travel-related expenses, business development expenses, including costs for business acquisition opportunities, business disposition related expenses, indirect costs such as insurance, professional fees and other general overhead expenses, and amortization of certain contract costs. Amortization of contract costs represent amounts, including sales commissions, that have been capitalized and reflect the incremental costs of obtaining and fulfilling a contract.

Research and development expenses consist of employee-related compensation and benefit expenses and third-party consulting fees of technology professionals, net of capitalized labor, incurred to develop our software-related products and services.

Amortization of purchased intangible assets includes the amortization of all identified intangible assets.

Other (Expense) Income, Net

Other (expense) income, net, includes equity in net income of unconsolidated affiliates that is generated from our equity method investments. Our equity method investments primarily consist of our interests in FFF Enterprises, Inc. (“FFF”) and Prestige Ameritech Ltd. (“Prestige”). Other (expense) income, net, also includes the change in fair value of our FFF put and call rights (see Note 6 - Fair Value Measurements), interest income and expense, realized and unrealized gains or losses on deferred compensation plan assets, gains or losses on the disposal of assets, and any impairment on our held-to-maturity investments.

Income Tax Expense

On August 11, 2020, we entered into the Merger Agreement by and among us, Premier Healthcare Alliance, LP (“Premier LP”) and BridgeCo, a wholly owned subsidiary of Premier Services, LLC formed for the sole purpose of merging with and into Premier LP. Pursuant to the Merger Agreement, (i) each of the issued and outstanding Class B common units of Premier LP was canceled and converted automatically into a right to receive one share of our Class A common stock, and (ii) all of the issued and outstanding shares of our Class B common stock beneficially held by the limited partners of Premier LP were canceled in accordance with our Certificate of Incorporation. As a result of the Merger, we simplified our tax structure whereby we and our subsidiaries formed one consolidated filing group for federal income tax purposes. See Note 14 - Income Taxes.

Adjusted Net Income, a Non-GAAP financial measure as defined below in “Our Use of Non-GAAP Financial Measures”, is calculated net of taxes based on our estimated annual effective tax rate for federal and state income tax, adjusted for unusual or infrequent items, as we are a consolidated group for tax purposes with all of our subsidiaries’ activities included. Prior to August 11, 2020, Adjusted Net Income was calculated as if we were one consolidated group for tax purposes. The rate used to compute Adjusted Net Income was 22% for the three and nine months ended March 31, 2021 and 26% for the three and nine months ended March 31, 2020.

Net Income Attributable to Non-Controlling Interest

For the nine months ended March 31, 2021, we recognized net income attributable to the limited partners of Premier LP through August 11, 2020, the date of the Merger. At March 31, 2021, we, through Premier Services, LLC (“Premier GP), the sole general partner of Premier LP, and Premier Services II, LLC, a Delaware limited liability company, wholly owned subsidiary of us and sole limited partner of Premier LP, held 100% interest in Premier LP. At June 30, 2020, we held 59% sole general partner interest in Premier LP. In addition to their equity ownership interest in us, our members held a 0% and 41% limited partner interest in Premier LP at March 31, 2021 and June 30, 2020, respectively (see Note 10 - Redeemable Limited Partners' Capital to the accompanying condensed consolidated financial statements).

Through our consolidated subsidiary, PRAM Holdings, LLC (“PRAM”), we hold an approximate 20% interest in Prestige through PRAM’s ownership of Prestige limited partnership units at March 31, 2021. We own approximately 26% of the membership interest of PRAM, with the remainder held by 16 member health systems, and recognized net income attributable to non-controlling interest for the 74% interest held by the 16 member health systems.

Through our consolidated subsidiary, DePre Holdings, LLC (“DPH”), we hold an approximate 49% interest in DePre, LLC (“DePre”) through DPH’s ownership of DePre membership interests at March 31, 2021. We own approximately 21% of the membership interest of DPH, with the remainder held by 34 member health systems, and recognized net income attributable to non-controlling interest for the 79% interest held by the 34 member health systems.

40

As of March 31, 2021, we own 97% of the equity interest in HDP and recognized net income attributable to non-controlling interest for the 3% of equity retained by University Hospitals Holdings, Inc.

Our Use of Non-GAAP Financial Measures

The other key business metrics we consider are EBITDA, Adjusted EBITDA, Segment Adjusted EBITDA, Adjusted Net Income (historically referenced as “Adjusted Fully Distributed Net Income”), Adjusted Earnings per Share (historically referenced as “Adjusted Fully Distributed Earnings per Share”) and Free Cash Flow, which are all Non-GAAP financial measures.

We define EBITDA as net income before income or loss from discontinued operations, net of tax, interest and investment income, net, income tax expense, depreciation and amortization and amortization of purchased intangible assets. We define Adjusted EBITDA as EBITDA before merger and acquisition related expenses and non-recurring, non-cash or non-operating items and including equity in net income of unconsolidated affiliates. For all Non-GAAP financial measures, we consider non-recurring items to be income or expenses and other items that have not been earned or incurred within the prior two years and are not expected to recur within the next two years. Such items include certain strategic and financial restructuring expenses. Non-operating items include gains or losses on the disposal of assets and interest and investment income or expense.

We define Segment Adjusted EBITDA as the segment’s net revenue less cost of revenue and operating expenses directly attributable to the segment excluding depreciation and amortization, amortization of purchased intangible assets, merger and acquisition related expenses and non-recurring or non-cash items and including equity in net income of unconsolidated affiliates. Operating expenses directly attributable to the segment include expenses associated with sales and marketing, general and administrative, and product development activities specific to the operation of each segment. General and administrative corporate expenses that are not specific to a particular segment are not included in the calculation of Segment Adjusted EBITDA. Segment Adjusted EBITDA also excludes any income and expense that has been classified as discontinued operations.

We define Adjusted Net Income as net income attributable to Premier (i) excluding income or loss from discontinued operations, net, (ii) excluding income tax expense, (iii) excluding the impact of adjustment of redeemable limited partners’ capital to redemption amount, (iv) excluding the effect of non-recurring or non-cash items, including certain strategic and financial restructuring expenses, (v) assuming the exchange of all the Class B common units for shares of Class A common stock, which results in the elimination of non-controlling interest in Premier LP and (vi) reflecting an adjustment for income tax expense on Non-GAAP net income before income taxes at our estimated annual effective income tax rate, adjusted for unusual or infrequent items. We define Adjusted Earnings per Share as Adjusted Net Income divided by diluted weighted average shares (see Note 12 - Earnings Per Share).

We define Free Cash Flow as net cash provided by operating activities from continuing operations less distributions and Tax Receivable Agreement (“TRA”) payments to limited partners and purchases of property and equipment. Free Cash Flow does not represent discretionary cash available for spending as it excludes certain contractual obligations such as debt repayments.

Adjusted EBITDA and Free Cash Flow are supplemental financial measures used by us and by external users of our financial statements and are considered to be indicators of the operational strength and performance of our business. Adjusted EBITDA and Free Cash Flow measures allow us to assess our performance without regard to financing methods and capital structure and without the impact of other matters that we do not consider indicative of the operating performance of our business. More specifically, Segment Adjusted EBITDA is the primary earnings measure we use to evaluate the performance of our business segments.

We use Adjusted EBITDA, Segment Adjusted EBITDA, Adjusted Net Income and Adjusted Earnings per Share to facilitate a comparison of our operating performance on a consistent basis from period to period that, when viewed in combination with our results prepared in accordance with GAAP, provides a more complete understanding of factors and trends affecting our business. We believe Adjusted EBITDA and Segment Adjusted EBITDA assist our Board of Directors, management and investors in comparing our operating performance on a consistent basis from period to period because they remove the impact of earnings elements attributable to our asset base (primarily depreciation and amortization), certain items outside the control of our management team, e.g. taxes, other non-cash items (such as impairment of intangible assets, purchase accounting adjustments and stock-based compensation), and non-recurring items (such as strategic and financial restructuring expenses) and income and expense that has been classified as discontinued operations from our operating results. We believe Adjusted Net Income and Adjusted Earnings per Share assist our Board of Directors, management and investors in comparing our net income and earnings per share on a consistent basis from period to period because these measures remove non-cash (such as impairment of intangible assets, purchase accounting adjustments and stock-based compensation) and non-recurring items (such as strategic and financial restructuring expenses), and eliminate the variability of non-controlling interest that results from member owner exchanges of Class B common units for shares of Class A common stock. We believe Free Cash Flow is an

41

important measure because it represents the cash that we generate after payment of tax distributions to limited partners and capital investment to maintain existing products and services and ongoing business operations, as well as development of new and upgraded products and services to support future growth. Our Free Cash Flow allows us to enhance stockholder value through acquisitions, partnerships, joint ventures, investments in related businesses and debt reduction.

Despite the importance of these Non-GAAP financial measures in analyzing our business, determining compliance with certain financial covenants in our Credit Facility, measuring and determining incentive compensation and evaluating our operating performance relative to our competitors, EBITDA, Adjusted EBITDA, Segment Adjusted EBITDA, Adjusted Net Income, Adjusted Earnings per Share and Free Cash Flow are not measurements of financial performance under GAAP, may have limitations as analytical tools and should not be considered in isolation from, or as an alternative to, net income, net cash provided by operating activities, or any other measure of our performance derived in accordance with GAAP.

Some of the limitations of the EBITDA, Adjusted EBITDA and Segment Adjusted EBITDA measures include that they do not reflect: our capital expenditures or our future requirements for capital expenditures or contractual commitments; changes in, or cash requirements for, our working capital needs; the interest expense or the cash requirements to service interest or principal payments under our Credit Facility; income tax payments we are required to make; and any cash requirements for replacements of assets being depreciated or amortized. In addition, EBITDA, Adjusted EBITDA, Segment Adjusted EBITDA and Free Cash Flow are not measures of liquidity under GAAP, or otherwise, and are not alternatives to cash flows from operating activities.

Some of the limitations of the Adjusted Net Income and Adjusted Earnings per Share measures are that they do not reflect income tax expense or income tax payments we are required to make. In addition, Adjusted Net Income and Adjusted Earnings per Share are not measures of profitability under GAAP.

We also urge you to review the reconciliation of these Non-GAAP financial measures included elsewhere in this Quarterly Report. To properly and prudently evaluate our business, we encourage you to review the condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report and to not rely on any single financial measure to evaluate our business. In addition, because the EBITDA, Adjusted EBITDA, Segment Adjusted EBITDA, Adjusted Net Income, Adjusted Earnings per Share and Free Cash Flow measures are susceptible to varying calculations, such Non-GAAP financial measures may differ from, and may therefore not be comparable to, similarly titled measures used by other companies.

Non-recurring and non-cash items excluded in our calculation of Adjusted EBITDA, Segment Adjusted EBITDA and Adjusted Net Income consist of stock-based compensation, acquisition and disposition related expenses, remeasurement of TRA liabilities, gain on FFF put and call rights, income and expense that has been classified as discontinued operations and other expense. More information about certain of the more significant items follows below.

Stock-based compensation

In addition to non-cash employee stock-based compensation expense, this item includes non-cash stock purchase plan expense of $0.1 million for both the three months ended March 31, 2021 and 2020 and $0.4 million and $0.3 million for the nine months ended March 31, 2021 and 2020, respectively (see Note 13 - Stock-Based Compensation to the accompanying condensed consolidated financial statements).

Acquisition and disposition related expenses

Acquisition related expenses include legal, accounting, and other expenses related to acquisition activities and gains and losses on the change in fair value of earn-out liabilities. Disposition related expenses include severance and retention benefits and financial advisor fees and legal fees related to disposition activities.

Remeasurement of TRA liabilities

On August 10, 2020, we exercised our right to terminate the TRA entered into as of September 25, 2013 and effective as of October 1, 2013 by and among us and the former limited partners of Premier LP by providing all former LPs a notice of the termination and the amount of the expected payment to be made to each LP pursuant to the early termination provisions of the TRA with a determination date of August 10, 2020.

Prior to termination of the TRA, we recorded TRA liabilities based on 85% of the estimated amount of tax savings we expected to receive, generally over a 15-year period, which were attributable to the initial purchase of Class B common units from the member owners made concurrently with the IPO and subsequent exchanges by member owners of Class B common units into Class A common stock or cash. Tax payments made under the TRA were made to the member owners as we realized tax benefits. Determining the estimated amount of tax savings we expected to receive required judgment as deductibility of goodwill amortization expense was not assured and the estimate of tax savings was dependent upon the actual realization of the tax benefit and the tax rates in effect at that time.

42

Gain or loss on FFF put and call rights

See Note 6 - Fair Value Measurements to the accompanying condensed consolidated financial statements.

43

Results of Operations

Results of operations for all periods presented have been retrospectively adjusted to reflect continuing operations unless otherwise indicated.

The following table presents our results of operations for the periods presented (in thousands, except per share data):

	Three Months Ended March 31,						Nine Months Ended March 31,
	2021			2020			2021			2020
	Amount		% of Net Revenue	Amount		% of Net Revenue	Amount		% of Net Revenue	Amount		% of Net Revenue
Net revenue:
Net administrative fees	$	146,553	31%	$	174,049	52%	$	424,537	34%	$	518,566	54%
Other services and support	107,375		23%	99,591		30%	304,020		25%	270,929		29%
Services	253,928		54%	273,640		82%	728,557		59%	789,495		83%
Products	215,995		46%	61,183		18%	511,080		41%	167,344		17%
Net revenue	469,923		100%	334,823		100%	1,239,637		100%	956,839		100%
Cost of revenue:
Services	46,980		10%	49,007		15%	125,852		10%	143,965		15%
Products	211,136		45%	54,121		16%	496,286		40%	150,415		16%
Cost of revenue	258,116		55%	103,128		31%	622,138		50%	294,380		31%
Gross profit	211,807		45%	231,695		69%	617,499		50%	662,459		69%
Operating expenses:
Selling, general and administrative	134,502		29%	115,289		34%	388,453		31%	315,311		33%
Research and development	715		—%	628		—%	2,013		—%	1,808		—%
Amortization of purchased intangible assets	10,400		2%	13,966		4%	33,864		3%	38,948		4%
Operating expenses	145,617		31%	129,883		38%	424,330		34%	356,067		37%
Operating income	66,190		14%	101,812		30%	193,169		16%	306,392		32%
Other (expense) income, net	(1,302)		—%	(24,435)		(7)%	(4,173)		—%	7,670		1%
Income before income taxes	64,888		14%	77,377		23%	188,996		15%	314,062		33%
Income tax expense (benefit)	13,444		3%	4,165		1%	(88,037)		(7)%	78,336		8%
Net income from continuing operations	51,444		11%	73,212		22%	277,033		22%	235,726		25%
Income from discontinued operations, net of tax	—		—%	5		—%	—		—%	1,009		—%
Net income	51,444		11%	73,217		22%	277,033		22%	236,735		25%
Net income from continuing operations attributable to non-controlling interest	(3,123)		(1)%	(35,055)		(10)%	(15,903)		(1)%	(132,189)		(14)%
Net income from discontinued operations attributable to non-controlling interest	—		—%	(3)		—%	—		—%	(480)		—%
Net income attributable to non-controlling interest	(3,123)		(1)%	(35,058)		(10)%	(15,903)		(1)%	(132,669)		(14)%
Adjustment of redeemable limited partners’ capital to redemption amount	—		nm	302,569		nm	(26,685)		nm	516,725		nm
Net income attributable to stockholders	$	48,321	nm	$	340,728	nm	$	234,445	nm	$	620,791	nm
Weighted average shares outstanding:
Basic	122,254			69,451			114,596			65,582
Diluted	123,116			122,470			115,365			124,030
Earnings per share attributable to stockholders:
Basic earnings per share attributable to stockholders	$	0.40		$	4.91		$	2.05		$	9.47
Diluted earnings per share attributable to stockholders	$	0.39		$	0.54		$	2.03		$	1.66

nm = Not meaningful

44

The following table provides certain Non-GAAP financial measures for the periods presented (in thousands, except per share data). Refer to “Our Use of Non-GAAP Financial Measures” for further information regarding items excluded in our calculation of Adjusted EBITDA and Segment Adjusted EBITDA.

	Three Months Ended March 31,						Nine Months Ended March 31,
	2021			2020			2021			2020
Certain Non-GAAP Financial Data:	Amount		% of Net Revenue	Amount		% of Net Revenue	Amount		% of Net Revenue	Amount		% of Net Revenue
Adjusted EBITDA	$	121,207	26%	$	155,889	47%	$	356,768	29%	$	444,550	46%
Non-GAAP Adjusted Net Income	$	78,535	17%	$	88,908	27%	$	232,023	19%	$	265,668	28%
Non-GAAP Adjusted Earnings Per Share	$	0.64	nm	$	0.73	nm	$	1.89	nm	$	2.14	nm

The following tables provide the reconciliation of net income from continuing operations to Adjusted EBITDA and the reconciliation of income before income taxes to Segment Adjusted EBITDA (in thousands). Refer to “Our Use of Non-GAAP Financial Measures” for further information regarding items excluded in our calculation of Adjusted EBITDA and Segment Adjusted EBITDA.

	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Net income from continuing operations	$	51,444	$	73,212	$	277,033	$	235,726
Interest and investment loss, net	3,225		9,966		8,742		9,849
Income tax expense (benefit)	13,444		4,165		(88,037)		78,336
Depreciation and amortization	19,337		25,777		55,904		75,690
Amortization of purchased intangible assets	10,400		13,966		33,864		38,948
EBITDA	97,850		127,086		287,506		438,549
Stock-based compensation	13,180		7,668		27,970		19,358
Acquisition and disposition related expenses	4,126		7,287		14,889		16,263
Remeasurement of tax receivable agreement liabilities	—		(902)		—		(24,584)
Loss (gain) on FFF put and call rights	5,195		13,906		21,621		(8,477)
Other expense, net	856		844		4,782		3,441
Adjusted EBITDA	$	121,207	$	155,889	$	356,768	$	444,550
Income before income taxes	$	64,888	$	77,377	$	188,996	$	314,062
Equity in net income of unconsolidated affiliates	(5,524)		(4,442)		(16,023)		(11,038)
Interest and investment loss, net	3,225		9,966		8,742		9,849
Loss (gain) on FFF put and call rights	5,195		13,906		21,621		(8,477)
Other (income) expense	(1,594)		5,005		(10,167)		1,996
Operating income	66,190		101,812		193,169		306,392
Depreciation and amortization	19,337		25,777		55,904		75,690
Amortization of purchased intangible assets	10,400		13,966		33,864		38,948
Stock-based compensation	13,180		7,668		27,970		19,358
Acquisition and disposition related expenses	4,126		7,287		14,889		16,263
Remeasurement of tax receivable agreement liabilities	—		(902)		—		(24,584)
Equity in net income of unconsolidated affiliates	5,524		4,442		16,023		11,038
Deferred compensation plan income (expense)	1,521		(5,476)		9,231		(2,484)
Other expense, net	929		1,315		5,718		3,929
Adjusted EBITDA	$	121,207	$	155,889	$	356,768	$	444,550

45

	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Segment Adjusted EBITDA:
Supply Chain Services	$	117,949	$	149,212	$	339,538	$	447,081
Performance Services	35,950		34,634		109,675		84,977
Corporate	(32,692)		(27,957)		(92,445)		(87,508)
Adjusted EBITDA	$	121,207	$	155,889	$	356,768	$	444,550

The following table provides the reconciliation of net income attributable to stockholders to Non-GAAP Adjusted Net Income and the reconciliation of the numerator and denominator for earnings per share attributable to stockholders to Non-GAAP Adjusted Earnings per Share for the periods presented (in thousands). Refer to “Our Use of Non-GAAP Financial Measures” for further information regarding items excluded in our calculation of Non-GAAP Adjusted Net Income and Non-GAAP Adjusted Earnings per Share.

	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Net income attributable to stockholders	$	48,321	$	340,728	$	234,445	$	620,791
Adjustment of redeemable limited partners’ capital to redemption amount	—		(302,569)		26,685		(516,725)
Net income attributable to non-controlling interest	3,123		35,058		15,903		132,669
Income from discontinued operations, net of tax	—		(5)		—		(1,009)
Income tax expense (benefit)	13,444		4,165		(88,037)		78,336
Amortization of purchased intangible assets	10,400		13,966		33,864		38,948
Stock-based compensation	13,180		7,668		27,970		19,358
Acquisition and disposition related expenses	4,126		7,287		14,889		16,263
Remeasurement of tax receivable agreement liabilities	—		(902)		—		(24,584)
Loss (gain) on FFF put and call rights	5,195		13,906		21,621		(8,477)
Other expense, net	2,897		844		10,126		3,441
Non-GAAP adjusted income before income taxes	100,686		120,146		297,466		359,011
Income tax expense on adjusted income before income taxes (a)	22,151		31,238		65,443		93,343
Non-GAAP Adjusted Net Income	$	78,535	$	88,908	$	232,023	$	265,668
Reconciliation of denominator for earnings per share attributable to stockholders to Non-GAAP Adjusted Earnings per Share
Weighted Average:
Basic weighted average shares outstanding	122,254		69,451		114,596		65,582
Dilutive securities	862		645		769		662
Class B shares outstanding (b)	—		52,374		—		57,786
Weighted average shares outstanding - diluted	123,116		122,470		115,365		124,030
Dilutive securities	—		—		—		—
Class B shares outstanding (b)	—		—		7,511		—
Non-GAAP weighted average shares outstanding - diluted	123,116		122,470		122,876		124,030

(a)Reflects income tax expense at an estimated effective income tax rate of 22% of non-GAAP adjusted net income before income taxes for the three and nine months ended March 31, 2021 and 26% of non-GAAP adjusted income before income taxes for the three and nine months ended March 31, 2020.

(b)For the nine months ended March 31, 2021, the effect of 7.5 million Class B commons were excluded from the GAAP diluted weighted average shares outstanding as they had an anti-dilutive effect. On a non-GAAP basis, the effect of 7.5 million Class B common units was included in the non-GAAP diluted weighted average shares outstanding.

46

The following table provides the reconciliation of earnings per share attributable to stockholders to Non-GAAP Adjusted Earnings per Share for the periods presented. Refer to “Our Use of Non-GAAP Financial Measures” for further information regarding items excluded in our calculation of Non-GAAP Adjusted Earnings per Share.

	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Earnings per share attributable to stockholders	$	0.40	$	4.91	$	2.05	$	9.47
Adjustment of redeemable limited partners’ capital to redemption amount	—		(4.36)		0.23		(7.88)
Net income attributable to non-controlling interest	0.03		0.50		0.14		2.02
Income from discontinued operations, net of tax	—		—		—		(0.02)
Income tax expense (benefit)	0.11		0.06		(0.77)		1.19
Amortization of purchased intangible assets	0.09		0.20		0.30		0.59
Stock-based compensation	0.11		0.11		0.24		0.30
Acquisition and disposition related expenses	0.03		0.10		0.13		0.25
Remeasurement of tax receivable agreement liabilities	—		(0.01)		—		(0.37)
Loss (gain) on FFF put and call rights	0.04		0.20		0.19		(0.13)
Other expense, net	0.02		0.01		0.09		0.05
Impact of corporation taxes (a)	(0.19)		(0.45)		(0.57)		(1.42)
Impact of dilutive shares (b)	—		(0.54)		(0.14)		(1.91)
Non-GAAP Adjusted Earnings Per Share	$	0.64	$	0.73	$	1.89	$	2.14

(a)Reflects income tax expense at an estimated effective income tax rate of 22% of non-GAAP adjusted net income before income taxes for the three and nine months ended March 31, 2021 and 26% of non-GAAP adjusted income before income taxes for the three and nine months ended March 31, 2020.

(b)Reflects impact of dilutive shares on a non-GAAP basis, primarily attributable to the assumed conversion of all Class B common units for Class A common stock.

Consolidated Results - Comparison of the Three Months Ended March 31, 2021 to 2020

Net Revenue

Net revenue increased by $135.1 million during the three months ended March 31, 2021 compared to the three months ended March 31, 2020, primarily due to an increase of $154.8 million in product revenue and an increase of $7.8 million in other services and support revenue, partially offset by a decrease of $27.5 million in net administrative fees revenue. The variances in the material factors contributing to the changes in consolidated net revenue are discussed further in “Segment Results” below.

Cost of Revenue

Cost of revenue increased by $155.0 million during the three months ended March 31, 2021 compared to the three months ended March 31, 2020, primarily due to an increase of $157.0 million in cost of product revenue, partially offset by a decrease of $2.0 million in cost of services revenue. The variances in the material factors contributing to the changes in consolidated cost of revenue are discussed further in “Segment Results” below.

Operating Expenses

Operating expenses increased by $15.7 million during the three months ended March 31, 2021 compared to the three months ended March 31, 2020, primarily due to an increase of $19.2 million in selling, general and administrative expenses. The variances in the material factors contributing to the changes in consolidated operating expenses are discussed further in “Segment Results” below.

Other Income, Net

Other income, net increased by $23.1 million during the three months ended March 31, 2021 compared to the three months ended March 31, 2020, primarily due to a decrease in the loss on the FFF put and call rights in the current period (see Note 6 - Fair Value Measurements to the accompanying condensed consolidated financial statements for further information) and the other than temporary impairment charges associated with held-to-maturity investments in the prior year period.

Income Tax Expense

For the three months ended March 31, 2021, we recorded tax expense of $13.4 million compared to tax expense of $4.2 million recorded during the three months ended March 31, 2020. The tax expense recorded during the three months ended March 31,

47

2021 and 2020 results in effective tax rates of 21% and 5%, respectively. The increase in the effective tax rate is largely driven by the prior year impact of the income tax benefit associated with the NOL carryback provisions under the CARES Act and the associated release of the valuation allowance in March 2020. See Note 14 - Income Taxes to the accompanying condensed consolidated financial statements for more information.

Net Income Attributable to Non-Controlling Interest

Net income attributable to non-controlling interest decreased by $32.0 million during the three months ended March 31, 2021 compared to the three months ended March 31, 2020, primarily due to the Merger, whereby net income attributable to non-controlling interest in Premier LP was not recorded after the Merger date of August 11, 2020. As of March 31, 2021, we owned a 99.999% controlling general partner interest and a 0.001% limited partnership interest in Premier GP. At June 30, 2020, the portion of net income attributable to the limited partners of Premier LP was 41%.

Partially offsetting the decrease was the addition of non-controlling interest for the portion of net income attributable to PRAM, DPH and HDP, which was 74%, 79% and 3%, respectively.

Adjusted EBITDA

Adjusted EBITDA, a Non-GAAP financial measure as defined in “Our Use of Non-GAAP Financial Measures”, decreased by $34.7 million during the three months ended March 31, 2021, compared to the three months ended March 31, 2020. The variances in the material factors contributing to the changes in consolidated Non-GAAP Adjusted EBITDA are discussed further in “Segment Results” below.

Consolidated Results - Comparison of the Nine Months Ended March 31, 2021 to 2020

Net Revenue

Net revenue increased by $282.8 million during the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020, primarily due to an increase of $343.7 million in product revenue and an increase of $33.1 million in other services and support revenue, partially offset by a decrease of $94.0 million in net administrative fees revenue. The variances in the material factors contributing to the changes in consolidated net revenue are discussed further in “Segment Results” below.

Cost of Revenue

Cost of revenue increased by $327.8 million during the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020, primarily due to an increase of $345.9 million in cost of product revenue, partially offset by a decrease of $18.1 million in cost of services revenue. The variances in the material factors contributing to the changes in consolidated cost of revenue are discussed further in “Segment Results” below.

Operating Expenses

Operating expenses increased by $68.3 million during the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020, primarily due to an increase of $73.1 million in selling, general and administrative expenses. The variances in the material factors contributing to the changes in consolidated operating expenses are discussed further in “Segment Results” below.

Other Income, Net

Other income, net decreased by $11.8 million during the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020, primarily due to the loss on the FFF put and call rights in the current period compared to the gain on the FFF put and call rights in the prior year period (see Note 6 - Fair Value Measurements to the accompanying condensed consolidated financial statements for further information) partially offset by an increase in deferred compensation plan income and the other than temporary impairment charges associated with held-to-maturity investments in the prior year period.

Income Tax (Benefit) Expense

For the nine months ended March 31, 2021, we recorded a tax benefit of $88.0 million compared to tax expense of $78.3 million recorded during the nine months ended March 31, 2020. The tax benefit and expense recorded during the nine months ended March 31, 2021 and 2020 results in effective tax rates of (47)% and 25%, respectively. The change in the effective tax rate is primarily attributable to the one-time deferred tax benefit associated with remeasurement of the deferred tax asset and valuation allowance release as a result of the Merger. See Note 14 - Income Taxes to the accompanying condensed consolidated financial statements for more information.

48

Net Income Attributable to Non-Controlling Interest

Net income attributable to non-controlling interest decreased by $116.8 million during the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020, primarily due to the Merger, whereby net income attributable to non-controlling interest was not recorded after the Merger date of August 11, 2020.

Partially offsetting the decrease was the addition of non-controlling interest for the portion of net income attributable to PRAM, DPH and HDP, which was 74%, 79% and 3%, respectively.

Adjusted EBITDA

Adjusted EBITDA, a Non-GAAP financial measure, decreased by $87.8 million during the nine months ended March 31, 2021, compared to the nine months ended March 31, 2020. The variances in the material factors contributing to the changes in consolidated Non-GAAP Adjusted EBITDA are discussed further in “Segment Results” below.

Segment Results

Supply Chain Services

The following table presents our results of operations and Adjusted EBITDA, a Non-GAAP financial measure, in the Supply Chain Services segment for the periods presented (in thousands):

	Three Months Ended March 31,							Nine Months Ended March 31,
Supply Chain Services	2021		2020		Change			2021		2020		Change
Net revenue:
Net administrative fees	$	146,553	$	174,049	$	(27,496)	(16)%	$	424,537	$	518,566	$	(94,029)	(18)	%
Other services and support	8,630		3,396		5,234		154%	18,307		8,439		9,868		117	%
Services	155,183		177,445		(22,262)		(13)%	442,844		527,005		(84,161)		(16)	%
Products	215,995		61,183		154,812		253%	511,080		167,344		343,736		205	%
Net revenue	371,178		238,628		132,550		56%	953,924		694,349		259,575		37	%
Cost of revenue:
Services	1,120		123		997		nm	2,627		278		2,349		845	%
Products	211,136		54,121		157,015		290%	496,286		150,415		345,871		230	%
Cost of revenue	212,256		54,244		158,012		291%	498,913		150,693		348,220		231	%
Gross profit	158,922		184,384		(25,462)		(14)%	455,011		543,656		(88,645)		(16)	%
Operating expenses:
Selling, general and administrative	49,714		45,512		4,202		9%	144,511		119,179		25,332		21	%
Research and development	72		—		72		—%	199		6		193		—	%
Amortization of purchased intangible assets	8,151		6,125		2,026		33%	24,205		14,318		9,887		69	%
Operating expenses	57,937		51,637		6,300		12%	168,915		133,503		35,412		27	%
Operating income	100,985		132,747		(31,762)		(24)%	$	286,096	$	410,153	$	(124,057)	(30)	%
Depreciation and amortization	1,238		771					3,403		2,274
Amortization of purchased intangible assets	8,151		6,125					24,205		14,318
Acquisition and disposition related expenses	2,053		4,871					9,684		9,204
Equity in net income of unconsolidated affiliates	5,319		4,431					15,907		10,865
Other expense	203		267					243		267
Segment Adjusted EBITDA	$	117,949	$	149,212	$	(31,263)	(21)%	$	339,538	$	447,081	$	(107,543)	(24)	%

Comparison of the Three Months Ended March 31, 2021 to 2020

Net Revenue

Supply Chain Services segment net revenue increased by $132.6 million, or 56%, during the three months ended March 31, 2021 compared to the three months ended March 31, 2020 largely due to an increase in product revenue of $154.8 million that was primarily driven by growth in commodity products and aggregated purchasing of certain products as well as the aggregated purchasing of PPE and other high demand supplies as a result of the COVID-19 pandemic. The increase in Supply Chain

49

Services segment net revenue is also due to a $5.2 million increased supply chain co-management fees as a result of the asset acquisition of Nexera.

These increases were partially offset by a decrease in net administrative fees of $27.5 million as a result of amendments to GPO Participation Agreements, effective as of July 1, 2020, lower utilization of GPO contracts and the related decline in the demand for supplies and services as a result of COVID-19 and amortization of the prepaid contract administrative fee share for one-time rebates paid by Acurity, Inc. to certain of its then members, as agreed to by Acurity, Inc. prior to entering into the Purchase Agreement (“Acurity prepaid contract administrative fee share”). These decreases in net administrative fees were partially offset by growth from further penetration of member purchased services, the addition of new categories and suppliers and the addition of new members to our contract portfolio.

Cost of Revenue

Supply Chain Services segment cost of revenue increased by $158.0 million during the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase in cost of revenue, driven by the aforementioned increase in product revenue, was greater than the increase in product revenue of $154.8 million primarily due to product costs in excess of the selling price that we incurred as a result of COVID-19.

Operating Expenses

Supply Chain Services segment operating expenses increased by $6.3 million during the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase was primarily due to an increase in selling, general and administrative expenses of $4.2 million driven by an increase in expenses associated with our fiscal year 2020 acquisition of Medpricer and the Acurity and Nexera asset acquisition partially offset by a decrease in employee travel and meeting expenses due to COVID-19. In addition, operating expenses increased by $2.0 million as a result of increased amortization of purchased intangible assets related to the fiscal year 2020 acquisitions.

Segment Adjusted EBITDA

Supply Chain Services Segment Adjusted EBITDA decreased by $31.3 million during the three months ended March 31, 2021 compared to the three months ended March 31, 2020, primarily due to the aforementioned decrease in net administrative fees and the increase in selling, general and administrative expenses largely due to our fiscal year 2020 acquisitions.

Comparison of the Nine Months Ended March 31, 2021 to 2020

Net Revenue

Supply Chain Services segment net revenue increased by $259.6 million, or 37%, during the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020 largely driven by an increase in product revenue of $343.7 million due primarily to the aggregated purchasing of PPE as a result of COVID-19 and growth in commodity products and aggregated purchasing of certain products. Supply Chain Services segment revenue also increased by $9.9 million due to supply chain co-management fees as a result of the asset acquisition of Nexera.

There has been a significant increase in demand for PPE and other supplies directly related to treating and preventing the spread of COVID-19, as well as replenishing and maintaining certain inventory levels, that has contributed significantly to the increase in product revenue. To the extent the COVID-19 pandemic subsides or becomes more manageable, we expect the market for these high demand products to stabilize and, accordingly, we anticipate product revenue growth rates to correspondingly decrease.

These increases were partially offset by a decrease in net administrative fees of $94.0 million primarily as a result of amendments to GPO Participation Agreements, effective as of July 1, 2020, lower utilization of GPO contracts and the related decline in the demand for supplies and services as a result of COVID-19 and amortization of the Acurity prepaid contract administrative fee share. These decreases in net administrative fees were partially offset by further penetration of member purchased services and the addition of new categories and suppliers.

We anticipate lower net administrative fees for the remainder of fiscal year 2021 due to amendments to GPO Participation Agreements and the ongoing impact from COVID-19. However, once the COVID-19 pandemic subsides and we move into fiscal year 2022, we expect our net administrative fees revenue to grow to the extent our existing members increase the utilization of our contracts and new members convert to our contract portfolio. Due to competitive market trends, we have experienced, and expect to continue to experience, requests, at times, to provide existing and prospective members and other

50

customers increases in revenue share on incremental or overall purchasing volume that could, if materially increased, adversely impact our revenues and overall financial performance.

Cost of Revenue

Supply Chain Services segment cost of revenue increased by $348.2 million during the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020 primarily due to the aforementioned increase in product revenue as well as higher costs for products that we incurred as a result of COVID-19. As a result of the COVID-19 pandemic, we expect higher costs in fiscal year 2021 due to increased demand in PPE. To the extent the COVID-19 pandemic subsides or becomes more manageable, we expect the market for these high demand products to stabilize and, accordingly, we anticipate our product costs to correspondingly decrease. However, once the COVID-19 pandemic subsides, we expect our cost of non-COVID-19-related product revenue to increase to the extent we are able to sell additional direct-sourced medical products to new and existing members and other customers. Depending on the underlying product sales mix in the future, increases in product revenues could reduce our gross profit as a percentage of our net revenue.

Operating Expenses

Supply Chain Services segment operating expenses increased by $35.4 million during the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020. The increase was primarily due to an increase in selling, general and administrative expenses of $25.3 million driven by an increase in expenses associated with our fiscal year 2020 acquisition of Medpricer and the Acurity and Nexera asset acquisition partially offset by a decrease in employee travel and meeting expenses due to the COVID-19 pandemic. In addition, operating expenses increased by $9.9 million as a result of increased amortization of purchased intangible assets related to the fiscal year 2020 acquisitions.

Segment Adjusted EBITDA

Supply Chain Services Segment Adjusted EBITDA decreased by $107.5 million during the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020, primarily due to the aforementioned decrease in net administrative fees and the increase in selling, general and administrative expenses largely due to our fiscal year 2020 acquisitions.

Performance Services

The following table presents our results of operations and Adjusted EBITDA in the Performance Services segment for the periods presented (in thousands):

	Three Months Ended March 31,							Nine Months Ended March 31,
Performance Services	2021		2020		Change			2021		2020		Change
Net revenue:
Other services and support	$	98,745	$	96,195	$	2,550	3%	$	285,713	$	262,490	$	23,223	9%
Net revenue	98,745		96,195		2,550		3%	285,713		262,490		23,223		9%
Cost of revenue:
Services	45,860		48,884		(3,024)		(6)%	123,225		143,687		(20,462)		(14)%
Cost of revenue	45,860		48,884		(3,024)		(6)%	123,225		143,687		(20,462)		(14)%
Gross profit	52,885		47,311		5,574		12%	162,488		118,803		43,685		37%
Operating expenses:
Selling, general and administrative	34,517		37,586		(3,069)		(8)%	102,488		106,522		(4,034)		(4)%
Research and development	643		628		15		2%	1,814		1,797		17		1%
Amortization of purchased intangible assets	2,249		7,841		(5,592)		(71)%	9,659		24,630		(14,971)		(61)%
Operating expenses	37,409		46,055		(8,646)		(19)%	113,961		132,949		(18,988)		(14)%
Operating income (loss)	15,476		1,256		14,220		nm	$	48,527	$	(14,146)	$	62,673	nm
Depreciation and amortization	15,947		23,109					46,104		67,232
Amortization of purchased intangible assets	2,249		7,841					9,659		24,630
Acquisition related expenses	2,073		2,416					5,205		7,059
Equity in net income of unconsolidated affiliates	205		11					116		173
Other expense	—		1					64		29
Segment Adjusted EBITDA	$	35,950	$	34,634	$	1,316	4%	$	109,675	$	84,977	$	24,698	29%

51

Comparison of the Three Months Ended March 31, 2021 to 2020

Net Revenue

Net revenue in our Performance Services segment increased by $2.6 million during the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase was primarily driven by incremental revenue associated with our acquisition of HDP in May 2020, growth in life sciences business and growth in the cost management and consulting services. This increase was partially offset by a reduction in the technology businesses due to lower revenue associated with enterprise analytics license agreements executed during the current period as compared to the prior year period and lower revenue as a result of the planned reduction and subsequent discontinuance of the Hospital Improvement Innovation Network (“HIIN”) contract in March 2020.

Cost of Revenue

Performance Services segment cost of revenue decreased by $3.0 million during the three months ended March 31, 2021 compared to the three months ended March 31, 2020, primarily due to a decrease in amortization of internally developed software applications, lower consulting expenses due to decreased utilization of third-party contractors and lower expenses as a result of the planned reduction and subsequent discontinuance of the HIIN contract in March 2020. These decreases were partially offset by incremental expenses associated with the HDP acquisition.

Operating Expenses

Performance Services segment operating expenses decreased by $8.6 million during the three months ended March 31, 2021 compared to the three months ended March 31, 2020 primarily due to $5.6 million of lower amortization of purchased intangible assets during the current period and decreased selling, general and administrative expenses of $3.1 million. The decrease in selling, general and administrative expenses was driven by a decrease in amortization of internally developed software applications and a decrease in employee travel and meeting expenses as a result of the COVID-19 pandemic.

Segment Adjusted EBITDA

Performance Services Segment Adjusted EBITDA increased by $1.3 million during the three months ended March 31, 2021 compared to the three months ended March 31, 2020 primarily due to the aforementioned increase in revenue and lower employee travel and meeting expenses due to the COVID-19 pandemic offset by incremental expenses associated with the HDP acquisition.

Comparison of the Nine Months Ended March 31, 2021 to 2020

Net Revenue

Other services and support revenue in our Performance Services segment increased by $23.2 million during the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020. The increase was primarily driven by growth across the technology businesses, including new enterprise analytics license agreements, as well as incremental revenue associated with our fiscal year 2020 acquisition of HDP. These increases were partially offset by lower demand in consulting services as a result of the COVID-19 pandemic and lower revenue as a result of the planned reduction and subsequent discontinuance of the HIIN contract in March 2020.

We expect our other services and support revenue to grow over the long-term to the extent we are able to expand our sales to existing members and as additional members and other customers, employer, payor and life sciences markets, begin to utilize our integrated platform of products and services.

Cost of Revenue

Performance Services segment cost of revenue decreased by $20.5 million during the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020, primarily due to a decrease in amortization of internally developed software applications, lower consulting expenses due to decreased utilization of third-party contractors and lower expenses as a result of the planned reduction and subsequent discontinuance of the HIIN contract in March 2020. These decreases were partially offset by incremental expenses associated with the HDP acquisition.

Operating Expenses

Performance Services segment operating expenses decreased by $19.0 million during the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020. The decrease was primarily due to a reduction in amortization of

52

purchased intangible assets of $15.0 million and a decrease in selling, general and administrative expenses of $4.0 million driven by a decrease in employee travel and meeting expenses due to COVID-19 and a decrease in amortization of internally developed software applications partially offset by an increase in expenses associated with the HDP acquisition.

Segment Adjusted EBITDA

Performance Services Segment Adjusted EBITDA increased by $24.7 million during the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020 primarily due to the aforementioned increase in revenue and decrease in selling, general and administrative expenses offset by incremental expenses associated with the HDP acquisition.

Corporate

The following table presents corporate expenses and Adjusted EBITDA for the periods presented (in thousands):

	Three Months Ended March 31,							Nine Months Ended March 31,
Corporate	2021		2020		Change			2021		2020		Change
Operating expenses:
Selling, general and administrative	$	50,271	$	32,191	$	18,080	56%	$	141,454	$	89,610	$	51,844	58%
Research and development	—		—		—		nm	—		5		(5)		nm
Operating expenses	50,271		32,191		18,080		56%	141,454		89,615		51,839		58%
Operating loss	(50,271)		(32,191)		(18,080)		56%	(141,454)		(89,615)		(51,839)		58%
Depreciation and amortization	2,152		1,897					6,397		6,184
Stock-based compensation	13,180		7,668					27,970		19,358
Remeasurement of tax receivable agreement liabilities	—		(902)					—		(24,584)
Deferred compensation plan income	1,521		(5,476)					9,231		(2,484)
Other income	726		1,047					5,411		3,633
Adjusted EBITDA	$	(32,692)	$	(27,957)	$	(4,735)	17%	$	(92,445)	$	(87,508)	$	(4,937)	6%

Comparison of the Three Months Ended March 31, 2021 to 2020

Operating Expenses

Corporate operating expenses increased by $18.1 million during the three months ended March 31, 2021 compared to the three months ended March 31, 2020, primarily due to an increase in deferred compensation plan expense due to market changes and incremental personnel costs related to the fiscal year 2020 acquisitions. These increases to operating expenses were partially offset by a decrease in employee travel and meeting expenses due to the COVID-19 pandemic.

Adjusted EBITDA

Adjusted EBITDA decreased by $4.7 million during the three months ended March 31, 2021 compared to the three months ended March 31, 2020, primarily due to incremental personnel costs related to the fiscal year 2020 acquisitions offset by a decrease in employee travel and meeting expenses due to the COVID-19 pandemic.

Comparison of the Nine Months Ended March 31, 2021 to 2020

Operating Expenses

Corporate operating expenses increased by $51.8 million during the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020, primarily due to the prior period net remeasurement of the TRA as a result of the change in North Carolina state income tax law, costs incurred in connection with our August 2020 restructuring, incremental personnel costs related to the fiscal year 2020 acquisitions and an increase in deferred compensation plan expense due to market changes. These increases to operating expenses were partially offset by a decrease in employee travel and meeting expenses due to the COVID-19 pandemic.

Adjusted EBITDA

Adjusted EBITDA decreased by $4.9 million during the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020, primarily due to incremental personnel costs related to the fiscal year 2020 acquisitions offset by a decrease in employee travel and meeting expenses due to the COVID-19 pandemic.

53

Off-Balance Sheet Arrangements

As of March 31, 2021, we did not have any off-balance sheet arrangements.

Liquidity and Capital Resources

Our principal source of cash has been cash provided by operating activities. From time to time we have used, and expect to use in the future, borrowings under our Credit Facility as a source of liquidity. Our primary cash requirements involve operating expenses, working capital fluctuations, revenue share obligations, tax payments, capital expenditures, dividend payments on our Class A common stock, if and when declared, repurchases of Class A common stock pursuant to stock repurchase programs in place from time to time, acquisitions and related business investments, and general corporate activities. Our capital expenditures typically consist of internally developed software costs, software purchases, and computer hardware purchases.

As of March 31, 2021 and June 30, 2020, we had cash and cash equivalents of $132.6 million and $99.3 million, respectively. As of March 31, 2021 and June 30, 2020, there were $200.0 million and $75.0 million, respectively, of outstanding borrowings under the Credit Facility. During the nine months ended March 31, 2021, we borrowed $225.0 million and repaid $100.0 million of borrowings under the Credit Facility, which was used for other general corporate purposes. In April 2021, we repaid $75.0 million of outstanding borrowings under the Credit Facility.

We expect cash generated from operations and borrowings under our Credit Facility to provide us with adequate liquidity to fund our anticipated working capital requirements, revenue share obligations, tax payments, capital expenditures, dividend payments on our Class A common stock, if and when declared, and repurchases of Class A common stock pursuant to stock repurchase programs in place from time to time. Our capital requirements depend on numerous factors, including funding requirements for our product and service development and commercialization efforts, our information technology requirements, and the amount of cash generated by our operations. We believe that we have adequate capital resources at our disposal to fund currently anticipated capital expenditures, business growth and expansion, and current and projected debt service requirements. However, strategic growth initiatives will likely require the use of one or a combination of various forms of capital resources including available cash on hand, cash generated from operations, borrowings under our Credit Facility, and other long-term debt and, potentially, proceeds from the issuance of additional equity or debt securities.

During the second half of fiscal 2020, COVID-19 became a global pandemic that spread throughout the United States and much of the rest of the world. The full extent to which the COVID-19 pandemic will impact our business, operating results, financial condition and liquidity will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions to contain it or treat its impact, including the timing, development and deployment of an effective vaccine, or recurrences of COVID-19 or similar pandemics. As discussed in Item 1A. “Risk Factors” in our 2020 Annual Report, as a result of the COVID-19 pandemic and potential future pandemic outbreaks, we face significant risks including but not limited to the following:

•We have experienced and may continue to experience demand uncertainty from both significant increases in demand for PPE, drugs and other products related to the treatment of COVID-19 and decreases in demand for non-COVID-19-related products.

•Our GPO member hospitals and non-acute care sites have experienced reduced or limited access for non-patients, including our field teams, consultants and other professionals, and travel restrictions have impacted our employees' ability to travel to our members' facilities.

•The global supply chain has been significantly disrupted due to stay at home orders, border closings and rapidly escalating shipping costs.

•We have and may continue to receive requests for contract modifications, payment waivers and deferrals, payment reductions or amended payment terms from our contract counterparties. In addition, several pharmacy suppliers have exercised force majeure clauses related to failure to supply clauses in their contracts with us.

•The impact of the COVID-19 pandemic could result in a prolonged recession or depression in the United States or globally that could harm the banking system, limit demand for all products and services and cause other seen and unforeseen events and circumstances, all of which could negatively impact us.

•In response to the COVID-19 pandemic, federal, state and local governments are issuing new rules, regulations, changing reimbursement eligibility rules, orders and advisories on a regular basis. These government actions can impact us, our members, other customers and suppliers.

54

Discussion of Cash Flows for the Nine Months Ended March 31, 2021 and 2020

A summary of net cash flows follows (in thousands):

	Nine Months Ended March 31,
	2021		2020
Net cash provided by (used in):
Operating activities	$	192,365	$	248,082
Investing activities	(149,291)		(171,954)
Financing activities	(9,794)		15,213
Operating activities from discontinued operations	—		9,338
Net increase in cash and cash equivalents	$	33,280	$	100,679

Net cash provided by operating activities decreased by $55.7 million for the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020. The decrease in net cash provided by operating activities was primarily due to lower profitability of our Supply Chain Services segment from lower net administrative fees revenue as a result of amendments to GPO Participation Agreements, effective as of July 1, 2020, lower utilization of GPO contracts and the related decline in the demand for supplies and services as a result of the COVID-19 pandemic and amortization of the Acurity prepaid contract administrative fee share. In addition, net cash provided by operating activities was impacted by changes in our net working capital, including higher levels of inventory, primarily driven by the impact of the aggregated purchasing of PPE as a result of the COVID-19 pandemic.

Net cash used in investing activities decreased by $22.7 million for the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020. The decrease in net cash used in investing activities is primarily due to a $15.2 million reduction in cash paid for business acquisitions and a reduction of $10.2 million in investments in unconsolidated affiliates as a result of no investments in unconsolidated affiliates in the current year. These decreases were offset by cash proceeds of $3.6 million received in the prior year from the liquidation of property and equipment in connection with our exit from specialty pharmacy operations in June 2019.

Net cash used in financing activities changed by $25.0 million for the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020. The change in net cash used in financing activities was driven by a $100.0 million decrease in net borrowings under the Credit Facility, cash dividends payments of $69.6 million and a $25.7 million payment on the outstanding notes payable to members (see Note 9 - Debt and Notes Payable). These were offset by a decrease of $150.1 million for prior year repurchases of Class A common stock under the fiscal year 2020 stock repurchase program and a $29.6 million reduction in distributions to limited partners of Premier LP as a result of the elimination of distributions in connection with the August 2020 restructuring.

Net cash provided by operating activities attributable to discontinued operations decreased by $9.3 million for the nine months ended March 31, 2021, compared to the nine months ended March 31, 2020 primarily due to payments on liabilities that were outstanding as of March 31, 2020.

Discussion of Non-GAAP Free Cash Flow for the Nine Months Ended March 31, 2021 and 2020

We define Non-GAAP Free Cash Flow as net cash provided by operating activities from continuing operations less distributions and TRA payments to limited partners and purchases of property and equipment. Free cash flow does not represent discretionary cash available for spending as it excludes certain contractual obligations such as debt repayments. A summary of Non-GAAP Free Cash Flow and reconciliation to net cash provided by operating activities for the periods presented follows (in thousands):

55

	Nine Months Ended March 31,
	2021		2020
Net cash provided by operating activities from continuing operations (a)	$	192,365	$	340,228
Purchases of property and equipment	(66,911)		(69,326)
Distributions to limited partners of Premier LP (b)	(9,949)		(39,590)
Payments to limited partners of Premier LP related to tax receivable agreements (b)	(24,218)		(17,425)
Non-GAAP Free Cash Flow	$	91,287	$	213,887

(a) Net cash provided by operating activities from continuing operations for the nine months ended March 31, 2020 excludes the impact of the Acurity prepaid contract administrative fee share, as defined above.

(b) Limited partners refers to member owners prior to the August 2020 restructuring.

Non-GAAP Free Cash Flow decreased by $122.6 million for the nine months ended March 31, 2021 compared to the nine months ended March 31, 2020. The decrease in Non-GAAP Free Cash Flow was primarily due to the aforementioned decrease in net cash provided by operating activities which was driven by lower net administrative fees revenue as a result of amendments to GPO Participation Agreements and lower utilization of GPO contracts as a result of COVID-19 as well as changes in our net working capital, including higher levels of inventory, primarily driven by the impact of the aggregated purchasing of PPE as a result of the COVID-19 pandemic. The net cash provided by operating activities for continuing operations for the nine months ended March 31, 2020 also includes the impact of the Acurity prepaid contract administrative fee share.

In addition, the change in Non-GAAP Free Cash Flow was due to higher TRA payments during the nine months ended March 31, 2021 which include the $10.5 million that was paid to limited partners of Premier LP who did not elect to execute a Unit Exchange and Tax Receivable Acceleration Agreement in connection with the August 2020 restructuring offset by the elimination of distributions to limited partners of Premier LP in connection with the August 2020 restructuring.

These decreases in Non-GAAP Free Cash Flow were offset by lower distributions to limited partners of Premier LP as a result of the August 2020 restructuring.

See “Our Use of Non-GAAP Financial Measures” above for additional information regarding our use of Non-GAAP Free Cash Flow.

Contractual Obligations

Notes Payable to Members

At March 31, 2021, we had commitments of $418.6 million, net of imputed interest of $17.8 million for obligations under notes payable which represents the aggregate early termination payments due to members in connection with the early termination of the TRA. Notes payable to members will be paid, without interest, in 18 equal quarterly installments commencing during the quarter ended March 31, 2021 and ending in the quarter ending June 30, 2025. See Note 9 - Debt and Notes Payable to the accompanying condensed consolidated financial statements for more information.

Other Notes Payable

At March 31, 2021, we had commitments of $9.3 million for other obligations under notes payable. Other notes payable have stated maturities between three to five years from the date of issuance and are non-interest bearing. See Note 9 - Debt and Notes Payable to the accompanying condensed consolidated financial statements for more information.

Credit Facility

Premier LP, along with its consolidated subsidiaries, PSCI and PHSI, as Co-Borrowers, Premier GP and certain domestic subsidiaries of Premier GP, as guarantors, entered into an unsecured Credit Facility, dated as of November 9, 2018. The Credit Facility has a maturity date of November 9, 2023, subject to up to two one-year extensions at the request of the Co-Borrowers and approval of a majority of the lenders under the Credit Facility. The Credit Facility provides for borrowings of up to $1.0 billion with (i) a $50.0 million sub-facility for standby letters of credit and (ii) a $100.0 million sub-facility for swingline loans. The Credit Facility also provides that Co-Borrowers may from time to time (i) incur incremental term loans and (ii) request an increase in the revolving commitments under the Credit Facility, together up to an aggregate of $350.0 million, subject to the approval of the lenders providing such term loans or revolving commitment increase. The Credit Facility includes an unconditional and irrevocable guaranty of all obligations under the Credit Facility by Premier GP, certain domestic subsidiaries of Premier GP and future guarantors, if any. Premier, Inc. is not a guarantor under the Credit Facility.

56

At our option, committed loans may be in the form of Eurodollar rate loans (“Eurodollar Loans”) or base rate loans (“Base Rate Loans”). Eurodollar Loans bear interest at the Eurodollar rate (defined as the London Interbank Offered Rate, or LIBOR, plus the Applicable Rate (defined as a margin based on the Consolidated Total Net Leverage Ratio (as defined in the Credit Facility))). Base Rate Loans bear interest at the Base Rate (defined as the highest of the prime rate announced by the administrative agent, the federal funds effective rate plus 0.50%, the one-month LIBOR plus 1.0% and 0.0%) plus the Applicable Rate. The Applicable Rate ranges from 1.000% to 1.500% for Eurodollar Loans and 0.000% to 0.500% for Base Rate Loans. In the event that LIBOR is no longer available, the Credit Facility states that interest will be calculated based upon rates offered to leading banks for comparable loans by leading banks in the London interbank market. At March 31, 2021, the interest rate for one-month Eurodollar Loans was 1.148% and the interest rate for Base Rate Loans was 3.250%. The Co-Borrowers are required to pay a commitment fee ranging from 0.100% to 0.200% per annum on the actual daily unused amount of commitments under the Credit Facility. At March 31, 2021, the commitment fee was 0.100%.

The Credit Facility contains customary representations and warranties as well as customary affirmative and negative covenants, including, among others, limitations on liens, indebtedness, fundamental changes, dispositions, restricted payments and investments. Under the terms of the Credit Facility, Premier GP’s consolidated total net leverage ratio (as defined in the Credit Facility) may not exceed 3.75 to 1.00 for four consecutive quarters, provided that, in connection with any acquisition for which the aggregate consideration exceeds $250.0 million, the maximum consolidated total net leverage ratio may increase to 4.25 to 1.00 for the four consecutive fiscal quarters beginning with the quarter in which such acquisition is completed. In addition, Premier GP must maintain a minimum consolidated interest coverage ratio (as defined in the Credit Facility) of 2.50 to 1.00 at the end of every fiscal quarter. Premier GP was in compliance with all such covenants at March 31, 2021.

The Credit Facility also contains customary events of default including, among others, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults of any indebtedness or guarantees in excess of $75.0 million, bankruptcy and other insolvency events, ERISA-related liabilities and judgment defaults in excess of $50.0 million, and the occurrence of a change of control (as defined in the Credit Facility). If any event of default occurs and is continuing, the administrative agent under the Credit Facility may, with the consent, or shall, at the request of a majority of the lenders under the Credit Facility, terminate the commitments and declare all of the amounts owed under the Credit Facility to be immediately due and payable. We may prepay amounts outstanding under the Credit Facility without premium or penalty provided that Co-Borrowers compensate the lenders for losses and expenses incurred as a result of the prepayment of any Eurodollar Loan, as defined in the Credit Facility.

Proceeds from borrowings under the Credit Facility may generally be used to finance ongoing working capital requirements, including permitted acquisitions, cash dividends, if and when declared, repurchases of Class A common stock pursuant to stock repurchase programs, in place from time to time, and other general corporate activities. We had $200.0 million outstanding borrowings under the Credit Facility at March 31, 2021 with $799.9 million of available borrowing capacity after reductions for outstanding borrowings and outstanding letters of credit. In April 2021, we repaid $75.0 million of outstanding borrowings under the Credit Facility.

The above summary does not purport to be complete, and is subject to, and qualified in its entirety by reference to, the complete text of the Credit Facility, which is filed as Exhibit 10.21 to the 2020 Annual Report. See also Note 9 - Debt and Notes Payable to the accompanying condensed consolidated financial statements.

Cash Dividends

On September 15, 2020, December 15, 2020, and March 15, 2021, we paid a cash dividend of $0.19 per share on outstanding shares of Class A common stock to stockholders of record on September 1, 2020, December 1, 2020, and March 1, 2021 respectively. On April 23, 2021, our Board of Directors declared a cash dividend of $0.19 per share, payable on June 15, 2021 to stockholders of record on June 1, 2021.

We currently expect quarterly dividends to continue to be paid on or about December 15, March 15, June 15, and September 15. However, the actual declaration of any future cash dividends, and the setting of record and payment dates as well as the per share amounts, will be at the discretion of our Board of Directors each quarter after consideration of various factors, including our results of operations, financial condition and capital requirements, earnings, general business conditions, restrictions imposed by our current credit facility and any future financing arrangements, legal restrictions on the payment of dividends and other factors our Board of Directors deems relevant.

57

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk

Our exposure to market risk related primarily to the increase or decrease in the amount of any interest expense we must pay with respect to outstanding variable-rate debt instruments. At March 31, 2021, we had $200.0 million outstanding borrowings under our Credit Facility. At March 31, 2021, a one-percent change in the weighted average interest rate charged on outstanding borrowings under the Credit Facility would result in a net change in interest expense over the next twelve months by $2.0 million.

We invest our excess cash in a portfolio of individual cash equivalents. We do not currently hold, and have never held, any derivative financial instruments. We do not expect changes in interest rates to have a material impact on our results of operations or financial position. We plan to ensure the safety and preservation of our invested funds by limiting default, market, and investment risks. We plan to mitigate default risk by investing in low-risk securities.

Foreign Currency Risk

Substantially all of our financial transactions are conducted in U.S. dollars. We do not have significant foreign operations and, accordingly, do not believe we have market risk associated with foreign currencies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

As of the end of the period covered by this Quarterly Report, we carried out an evaluation under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures. Based upon our evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2021.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

58

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

We participate in businesses that are subject to substantial litigation from time to time. We are periodically involved in litigation, arising in the ordinary course of business or otherwise, which from time to time may include claims relating to contractual disputes, product liability, tort or personal injury, employment, antitrust, intellectual property or other commercial or regulatory matters. If current or future government regulations are interpreted or enforced in a manner adverse to us or our business, including without limitation those with respect to antitrust or healthcare laws, we may be subject to enforcement actions, penalties, damages and material limitations on our business.

Furthermore, as a public company, we may become subject to stockholder derivative or other similar litigation.

From time to time we have been named as a defendant in class action or other antitrust lawsuits brought by suppliers or purchasers of medical products. Typically, these lawsuits have alleged the existence of a conspiracy among manufacturers of competing products, distributors and/or operators of GPOs, including us, to deny the plaintiff access to a market for certain products to raise the prices for products and/or limit the plaintiff’s choice of products to buy. We believe that we have at all times conducted our business affairs in an ethical and legally compliant manner and have successfully resolved all such actions. No assurance can be given that we will not be subjected to similar actions in the future or that any such existing or future matters will be resolved in a manner satisfactory to us or which will not harm our business, financial condition or results of operations.

Additional information relating to certain legal proceedings in which we are involved is included in Note 16 - Commitments and Contingencies to the accompanying condensed consolidated financial statements, which information is incorporated herein by reference.

Item 1A. Risk Factors

During the quarter ended March 31, 2021, there were no material changes to the risk factors disclosed in Item 1A. “Risk Factors” in the 2020 Annual Report.

Item 5. Other Information

On April 23, 2021, our Board of Directors declared a cash dividend of $0.19 per share, payable on June 15, 2021 to stockholders of record on June 1, 2021. Declaration of any future cash dividends will be at the discretion of our Board of Directors after consideration of various factors, including our results of operations, financial condition and capital requirements, earnings, general business conditions, restrictions imposed by our current credit facility and any future financing arrangements, legal restrictions on the payment of dividends and other factors our Board of Directors deems relevant.

59

Item 6. Exhibits

Exhibit No.	Description
10.1	First Amendment to Senior Executive Employment Agreement effective February 1, 2021, by and between Susan D. DeVore and Premier Healthcare Solutions, Inc. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on February 2, 2021). +
10.2	Senior Executive Employment Agreement, effective May 1, 2021, by and between Michael J. Alkire and Premier Healthcare Solutions, Inc. (Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on February 2, 2021). +
31.1	Certification as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
31.2	Certification as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32.1	Certification required by 18 United States Code Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.‡
32.2	Certification required by 18 United States Code Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.‡
101	Sections of the Premier, Inc. Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, formatted in iXBRL (Inline eXtensible Business Reporting Language), submitted in the following files:
101.SCH	Inline XBRL Taxonomy Extension Schema Document.*
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.*
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.*
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.*
104	The cover page from the Premier, Inc. Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, formatted in Inline XBRL (included in Exhibit 101).*

*    Filed herewith.

+    Indicates a management contract or compensatory plan or arrangement

‡    Furnished herewith.

60

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.

			PREMIER, INC.
Date:	May 4, 2021	By:	/s/ Craig S. McKasson
		Name:	Craig S. McKasson
		Title:	Chief Administrative and Financial Officer and Senior Vice President
			Signing on behalf of the registrant and as principal financial officer and principal accounting officer

61